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ON THE COVER 
On the cover is a photograph of a section of
healthy mouse hippocampus tissue (near the
dentate gyrus) at 30 days of age. The tissue is
stained for nuclei (blue), astrocytes (green), and
glucose transporter GLUT8 (red). The image was
produced during research conducted by Madhuri
Rao, MSII.
Photos like Rao’s, capturing the beauty and
intricacy of science, are featured annually in the
George Washington University (GW) School
of Medicine and Health Sciences (SMHS) Art
of Science Contest. The competition began in
2018 as a means of highlighting the research that
SMHS medical students, graduate students, and
postdoctoral fellows are conducting. 
This year, more than 17 images were submitted,
an increase from last year’s competition, and fve
entries were chosen as winners.
A grand prize of $250 was awarded to Brett
Eaton, a PhD student who submitted an image of
the Marburg virus budding from infected dendritic
cells. Prizes of $100 were awarded to four other
entrants, all GW PhD students — Rachel Burga,
A student-led research publication of the George Washington University School of Medicine and Health Sciences | Spring 2019, Volume XII 
Samantha Dow, Naemeh Pourshafe, and Jessica
Schenck. 
The winning images will be displayed in Ross 
Hall, alongside the winners from last year. 
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Letters: 
From the Editors: 
A s  p a r t  o f  t h e  G e o r g e  
Wa s h i n g t o n  Un i v e r s i t y  
(GW ) School of Medicine
and Health Sciences’ (SMHS) 
mission to educate, research,
and heal, GW medical stu-
dents have the opportunity to 
conduct research in a multi-
tude of felds. The William H. 
Beaumont Medical Research
Honor Society aims to pro-
mote inquiry-based research
to train physician-scientists for
the future. This journal, run
by the William H. Beaumont 
Society, is an entirely student-
r un publication including
research conducted by GW
medica l students while in
medical school. This year’s
collection of abstracts refects 
a sample of the diverse student 
research being conducted at
SHMS from basic science to
clinical research to public
health initiatives. 
As co-presidents of the
William H. Beaumont Medical
Research Honor Society, we
aim to provide a forum to learn
about peer research, inspire
future and matriculating med-
ical students, and serve as an
outlet to share research experiences of GW
medical students. We hope that this journal 
inspires a dialogue to continue the sharing
of new knowledge and passion for research
Neil Almeida, MSII 
Abby Pepin, MSII 
amongst our students, faulty, and staf. We
aim to support GW’s goal to expand and
enhance research experiences for its students
as an opportunity to learn and become future 
leaders in medicine and health sciences felds. 
We would like to ofer our congratulations 
to this year’s William H. Beaumont Medical 
Honor Society Student Research Award win-
ners. These individuals and their research
projects stood out as exceptional in quality
among their peers. 
This year’s edition would not have been pos-
sible without the support of many individuals.
We would like to thank former presidents,
Janine Amirault and Sarah McCormack, for 
their continued involvement and support of
this organization. We would like to thank
our faculty adviser, Dean Alison Hall, for her 
wisdom and support. We would also like to
thank the SMHS Ofce of Communications 
and Marking for the design and produc-
tion of this year’s edition. Finally, we would
like to thank our classmates and peers who
volunteered their time to edit the abstracts
submitted, without whom this journal could 
not exist. 
On behalf of the William H. Beaumont
Medical Research Honor Society’s executive 
board and members, we hope you enjoy the
2019 edition of Fusion! 
Neil Almeida, MSII 
Abby Pepin, MSII 
Co-Presidents of the William H  Beaumont 
Medical Research Honor Society 
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Letters: 
From the Faculty Adviser: 
It’s an honor to assist with this edition of
Fusion magazine that highlights research done
by medical students at the George Washington
University (GW) School of Medicine and
Health Sciences. 
You will fnd examples of the broad range of
research pursued by students, from basic bio-
medical discovery to clinical and translational
research with patients to initial translation to 
practice and communities, on every page of
Fusion. In their submissions, medical students
described numerous sophisticated approaches,
including chart review, data collection, molec-
ular biology techniques, feld studies, study
design, assisting in IRB applications, and sta-
tistical analyses to name just a few. It is always 
a challenge to select the abstract winners from
a collection of such excellent projects. 
I would also like to thank the research
mentors who host students in their programs 
here at GW and in our partner institution
Children’s National Health Center, and in
research programs at the nearby NIH campus
and other institutions around the nation.
Mentorship is key in engaging students and
encouraging research careers in academic
health centers.
Medical students have rich opportunities 
for involvement in research. About 20 percent
of each class joins the clinical 
and translational research
scholarly concentration, that
includes longitudina l lec-
tures, summer research with
an abstract and poster, and
additional elective clerkships
in research. But you don’t have 
to be in the scholarly concen-
tration to do research! Many
students compete for external 
research fellowships as well as 
internal WT Gill and Health 
Services Research summer fel-
lowships. Students are encour-
aged to present — and to learn 
— at GW’s Research Days in
April each year.
Fusion magazine is just one efort by the
William H. Beaumont Research Honor
Society to engage GW medical students in the
excitement and impact of research. I welcome 
you to explore p. 4–5 and for additional ways to
join this community of clinician-investigators.
Alison K. Hall, PhD 
Associate Dean for Research Workforce
Development, Professor of Neurology 
Alison K  Hall, PhD 
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Numerous Opportunities for Medical Students to Engage in Research + Scholarship 
YEAR-OUT 
Stephen Langerman is taking the 2018–19
year off to conduct research as part of the
National Institutes of Health (NIH)-Medical
Research Scholars Program. He will study
the infuence of social
factors, such as crime,
poverty, and dis-
crimination on health
outcomes with Tiffany
M. Powell-Wiley, MD,
MPH, who heads the
Social Determinants
of Obesity and
Cardiovascular Risk
Laboratory at NIH. 
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RESEARCH SCHOLARLY
CONCENTRATION 
Last year, 32 MD students elected
to join the Clinical and Translational
Research Scholarly Concentration.
In this program, students conduct
mentored research over the
summer between frst and second
year, attend research lectures, and
continue with research scholarships.
For details, see https://tinyurl.com/ 
ybpn74cl. 
Taniya Walker, MSII, won a 2018 Gill Fellowship to 
conduct cardiology research on the effects of computed 
tomography scan fndings on the outcomes of
transcatheter aortic valve replacement  
GW RESEARCH FELLOWSHIPS 
A number of competitive scholarship 
programs are available to assist in 
funding exceptional projects in health 
care and medicine. In 2018, 31 students 
won a Gill Summer Research Fellowship 
and 57 students won a Health Services 
Scholarship. For details,see 
https://tinyurl.com/ybu4z3w5 and
https://tinyurl.com/y8ltewa9. 
RESEARCH DAYS AT GW 
GW Research Days is an April annual event that celebrates research
across GW. Students and postdoctoral fellows present posters and oral
presentations and compete for cash prizes.
See https://researchdays.gwu.edu/. 
At Research Day 2018, Nicole Casasanta, Sarit Toltzis, Dara Baker, and Christina Pugliese accepted the
William Beaumont Research Award from former Fusion editors, Sarah McCormack and Janine Amirault  
FUSION 
Fu  s  i o  n  i  s  G W  ’s  
a n n u a l  m e  d i c  a l  
s tudent research
journal. It is a forum
to share research
done by GW medical
students with the
l  a rg e  r  re s  ea  rc  h  
c  o  m m u n  i  t  y .  I  n  
2019, 35 student
research abstracts
were published. The
Beaumont Society
seeks Fusion editors
each year. 
5 To learn more, please contact the Office of Student Professional Enrichment smhs.gwu.edu/ospe.
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EXTERNAL FELLOWSHIPS 
Medical students may elect to take a year off from the MD program 
to conduct research full-time at GW, NIH, or other institutions. This 
can be a great way to fully immerse yourself in a research project 
and form connections at other institutions. External fellowship 
opportunities are listed at https://tinyurl.com/y9vj54gj. 
Third-year SMHS MD student Maggie Beatson, at left, is a Brown University 
Dermatoepidemiology Research Fellow, studying predictors of skin cancer  
METEOR PROGRAM 
The Mentored Experience to Expand Opportunities in 
Research (METEOR) program is a competitive fellowship 
for underrepresented-in-medicine
students. Students
are supported 
for a pre-
matriculation 
research
summer and
enroll in the 
research track.
https://tinyurl. 
com/y86oxwmb 
Students submit artistic images 
of their research for cash prizes. 
The award highlights the 
breadth and beauty of research 
done at GW. Aslam Akhtar, 
MSII, was last year’s grand prize 
winner. See https://tinyurl.com/ 
ybr8l26g 
RESEARCH PRIZES 
The 2018 Walter Freeman Research 
Award for best research paper 
was presented to (from left) Jason 
Chien and Peter Mullins by Lorenzo 
Norris, MD. 
The 2018 Doris DeFord Speck 
and George Speck Endowed 
Prize was awarded to Laura 
Tiedemann (at right) for her 
research on neonatal intensive 
care management. 
WILLIAM H. BEAUMONT 
RESEARCH HONOR
SOCIETY 
The Beaumont Research Honor 
Society was established to 
educate and inform medical 
students about research. Any 
GW medical student interested 
in research is welcome to 
join. 2018-2019 Co-Presidents 
are Neil Almeida and Abby 
Pepin. See https://tinyurl.com/ 
y7yuwr6w 
TRAVEL AWARDS 
Medical students are
encouraged to apply
for outside funding
for summer or year-
out research, or for
travel to meetings.
Visit the Scholarly
Concentration website
to see a list of oppor-
tunities for summer
research, travel, and
yearlong fellowships. 
See tinyurl.com/ 
y9vj54gj 
CTSA 
The Clinical and 
Translational Science
Award (CTSA) is a joint 
NIH award between GW 
and Children’s National 
Health System to conduct 
“bench to bedside” 
research. 
ART OF SCIENCE IMAGE CONTEST 
METEOR students Guido Pelaez, MS1,
and Juan Nogues, MSII 
6 Fusion ♦ 2019
 
 
 
        
 
 
 
 
 
 
    
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
  
 
 
 
 
 
  
 
 
 
 
  
 
  
 
 
  
 
 
  
William H. Beaumont Research Prize Winners: 
Evaluation of Longitudinal Antibody Responses in Zika-
Infected Individuals from Colombia 
Maria Abigail 
Cerezo, MSII
CO-AUTHORS:
Grace Mantus 1 
Liliana Encinales 2 
Andres Angelo
Cadena Bonfanti 3,4 
Nelly Pacheco 2 
Aileen Chang, MD, MPH 5 
ADVISER: Rebecca Lynch, DPT 5 
1 Emory University
2 Allied Research Society LLC
3 Universidad Simón Bolívar
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4 La Clinica de La Costa Ltda
5 The George Washington University School
of Medicine and Health Sciences 
Since the Zika epidemic in 2015,
there have been striking associations
between Zika virus (ZIKV) infec-
tion and neurological complications,
sequelae which are most devastat-
ingly seen in fetal development.1,2 As 
a result, there is an urgent need for
a vaccine against Zika. However, in
order to elicit protective, neutral-
We found that FL responses were signifcantly
stronger in people who did not develop GBS,
and that DIII responses were undetectable
in all patients. 
izing antibodies there is a critical
need-to-know of how pre-existing
immunity to Dengue virus afects the
antibody response to Zika infection.
We have previously observed that
people who developed Guillain-Barre
syndrome (GBS) had higher titers of
FIGURE 1: Comparison of antibody titers from patients in Colombia, South America, at
one and two years post-Zika infection Titers were evaluated through indirect ELISA assays 
The reciprocal plasma dilution at which binding was at 50% is graphed (EC50) This plot
depicts a gradual waning of the memory antibody response found within the plasma 
Dengue and Zika neutralizing anti-
bodies than those who did not develop
GBS during Zika infection.3 This 
study hypothesizes that in regions
endemic for f lavivirus
infection, individuals
who developed GBS and
had high neutralizing
antibody titers will have
antibodies that target
diferent viral epitopes 
from those who do not.
To conduct this study,
cl inica l ly diagnosed
plasma samples taken
from Zika-infected persons living
in Colombia, South America, were
tested for the presence and strength
of memory antibodies at two diferent
time points after virus clearance. Sera
were collected at one year (mean 1.3
years) and two years (mean 2.3 years)
post-Zika infection and were tested
against the ZIKV E (envelope) pro-
tein. As expected, all serum samples
bound highly to ZIKV E monomer
protein with detectable waning in
titer over one year (Figure 1). In order
to map the targeted viral epitopes,
we ran competition ELISAs using
known monoclonal antibodies, 4G2
and ZK67. These antibodies target
the fusion loop (FL) and Domain
III (DIII) of the E protein respec-
tively. Interestingly, we found that
the majority of sera contained anti-
bodies targeting the FL but not DIII.
Therefore, we investigated whether
there were clinical differences in
people who did or did not develop
Guillain-Barre syndrome (GBS). We
found that FL responses were signif-
cantly stronger in people who did not
develop GBS, and that DIII responses
7 BEAUMONT RESEARCH PRIZE WINNERS
 
 
 
  
 
 
 
 
 
  
 
 
 
 
  
     
 
   
 
• I 
• I 
• 
• 
• 
• 
• I 
I 
• I 
were undetectable in all patients
(Figure 2). Our future direction is to
expand this dataset to map epitopes
found on the ZIKV E dimer, which 
will better refect the natural confor-
mation of ZIKV E protein.
REFERENCES 
1. Parra B, Lizarazo J, Jiménez-Arango JA,
Zea-Vera AF, González-Manrique G,
Vargas J, et al. Guillain-Barré Syndrome 
Associated with Zika Virus Infection
in Colombia. N Engl J Med. 2016 Oct
20;375(16):1513–23.
2. da Si lva IR F, Frontera JA, Bispo de
Filippis AM, Nascimento OJMD, RIO-
GBS-ZIKV Research Group. Neurologic 
Complications Associated with the Zika 
Virus in Brazilian Adults. JAMA Neurol. 
2017 Aug 14. 
3. Ly nch R M, Mantus G, Encina les L ,
Pacheco N, Li G, Porras A, et al. Aug-
mented Zika and Dengue Neutralizing
Antibodies Are Associated with Guillain-
Barré Syndrome. The Journal of infectious
diseases. 2018 Aug 3. 
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FIGURE 2: Graphs of Plasma Binding Competition to Zika E Monomer Protein with 
Two Known Antibidies The percent binding competition to E protein at a plasma dilution 
of 1:20 is graphed to (A) anti-fusion loop antibody 4G2 and (B) anti-DIII antibody ZK67 
Each dot represents an individual plasma and is graphed by disease status of having a 
diagnosis of GBS or Zika infection alone There is signifcantly less competition (fusion 
loop antibodies) in the plasma from patients diagnosed with GBS by Mann-Whitney 
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 Prevention of Cardiovascular Thrombosis 
Through Inhibition of Coagulation Factor XII 
Sharjeel 
Chaudhry, MSIII
ADVISER: Robert
Flaumenhaft, MD
PhD
Beth Israel
Deaconess, Harvard
Medical School
Discover y of an antithrombotic
therapy that does not cause bleeding 
would be a transformative advance in 
the management of conditions such
as myocardial infarction, stroke, and 
venous thromboembolic disease.1 
One promising approach is inhibition
of factor XII (FXII/FXIIa), which
has been demonstrated to be throm-
boprotective in preclinical models.2 
Importantly, severe congenital FXII 
deficiency is not associated with
bleeding and FXII inhibition does
not augment bleeding in animal
models.3-4 Despite its potential as a
therapeutic target, the physiological 
mechanisms of FXII recruitment to 
sites of injury and its activation by
platelets remains poorly understood.5 
To explore the binding and activation
of FXII by platelets during thrombus 
formation, we stimulated platelet rich
plasma with PAR-1 agonist peptide
SFLLRN and measured the thrombin
generating capacity of platelets by
cleavage of a fuorogenic substrate in 
the presence of anti-FXIIa antibody, 
anti-TF antibody, and anti-FVIIa
antibody. We also stimulated washed 
platelets with SFLLRN and tested
the ability of the various platelet
fractions, including from a patient
with Hermansky Pudlak Syndrome
(HPS), to generate thrombin and
FXIIa. Sim i la rly, we measu red 
FIGURE 1: Platelet-based thrombin 
generation is FXXII-dependant  Platelet-
rich plasma was stimulated with 50 μM 
of the PAR-1 agonist peptide SFLLRN 
(SF), and thrombin generation at 60 
minutes was measured by cleavage of
a furogenic substrate in the presence 
of (A) X210-C01, (B) anti-TF antibody,
and (C) anti-FVIIa antibody These 
results demonstrate that stimulated 
platelets can actively support thrombin 
generation via a FXII-dependant 
pathway  ** p <0 05 compared to 
control by Kruskal-Wallis with Dunn’s 
post-test 
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platelet-dependent FXIIa genera-
tion in the presence of CaEDTA, a
specifc zinc chelator, to test whether 
zinc was required for FXII binding
and activation. We next interrogated 
whether phosphatidylserine (PS),
a negatively-charged phospholipid
expressed on the surface of stimulated
platelets, was responsible for FXII
activation using lactadherin, a phos-
phatidylserine blocker, and liposomes
containing increasing concentrations
of 80% phosphatidylcholine and 20% 
phosphatidylserine (PC/PS). We used
platelet fow cytometry with FITC-
labeled FXII, bead-immobilized
immunoprecipitation, and mass spec-
trometry to investigate a potential
platelet binding partner for FXII. We
found that stimulated, but not resting
platelets, are able to support thrombin
generation via a FXII-dependent
9 BEAUMONT RESEARCH PRIZE WINNERS
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
--­
···•·· 
. ~ .................................. . 
I', 
········••' . 
WT PLATELETS HPS PLATELETS A B 
8 0✖106 4✖10-5 pathway (Figure 1). We demonstrated
** that the FXIIa-generating capacity of
6 0✖106 3✖10-5 
Fl
uo
re
sc
en
ce
 (R
FU
/m
 in
) 
** 
** 
** 
FX
IIa
 G
en
er
at
io
n 
(R
U)
 
0 0 
platelets is contained in the insoluble 
fraction, not the releasate (Figure 2).
Evaluation of the interaction between
FXII and the platelet surface by fow 
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1✖10-5 2 0✖106 cytometry showed that FXII-FITC
binds to stimulated platelets in a spe-
cifc manner requiring cationic zinc.
Platelet-dependent FXIIa genera-
tion was inhibited by the presence of 
CaEDTA (Figure 3). We found that
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 (μg/M l) PS blockade with lactadherin prevents
platelet-dependent FXIIa generation,
while the addition of PS-containing 
FIGURE 2: The FXIIa and thrombin-generating activity of platelets is not contained
in releasate  (A) Washed platelets (2 7 x 109) were stimulated with 100 μM SFLLRN, and
liposomes to plasma did not trigger the ability of the indicated fractions to generate FXIIa was measured by a FXIIa-specifc
FXIIa production (Figure 3). These chromogenic substrate  **p<0 05 Mann-Whitney U test  (B) Platelet-rich plasma (PRP)
results suggest that PS is necessary from a patient with Hermansky Pudlak Syndrome (HPS) was stimulated with 50 μM 
but not sufcient for FXII activation SF and thrombin generation at 60 minutes with measured by cleavage of furogenic
substrate in the presence of increasing concentrations of X210-C01  **p<0 05 compared
Continued on p. 10 to control by Kruskal-Wallis with Dunn’s post-test  
FIGURE 3: FXII binding to activated platelets in zinc- and phosphatidylserine-
dependent  (A) Washed platelets were stimulated with 50μM SFLLRN and 
binding to increasing concentrations of FITC-labeled FXII was assessed by 
fow cytometry  (B) Platelets were stimulated with 50μM SFLLRN and platelet-
dependent FXIIa generation was measured using a chromogenic substrate in the 
presence of increasing concentrations of (B) CaEDTA, a specifc zinc chelator, (C) 
lactadherin, and (D) liposomes containing 80% phosphatidylcholine and 20% 
phosphatidylserine (PC/PS) 
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and that another platelet surface
constituent is required. Using co-
immunoprecipitation of FXII with
binding partners from platelet lysate 
followed by mass spectrometry, we
identifed candidate platelet surface
proteins that bind with FXII in the 
presence of zinc. Factor XII binds
the platelet surface in a specific,
zinc-dependent manner, which is
followed by its activation in a process 
that requires PS. Together, these
results may explain the longstanding 
clinical observation that platelets are 
crucial for arterial thrombosis but
relatively less important in venous
clotting. Greater insight into this
mechanism would help address an
important scientific question and
aid in the much-needed development 
of antithrombotic medications that
carry minimal risk of hemorrhage. 
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CyTOF Analysis Provides Insight into Immune Response to 
H3 327M Neoantigen Peptide Vaccine in Glioma Patients 
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Gliomas are the most common brain
tumor found in children and comprise
half of all pediatric central nervous
system (CNS) tumors.1 Difuse mid-
line glioma, H3 K27M-mutant is a
novel entity describing a classifcation
of tumors of the CNS, predominantly
arising in pediatric patients, located 
within midline structures, and car-
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Pr141Di :: 141Pr_CD3 
0 101 102 103 104 
Pr141Di :: 141Pr_CD3 
rying a poor prognosis. K27M muta-
tions in H3F3A or HIST1H3B/C,
encoding the histone variants H3.1 and
H3.3, have been shown to be critical
for gliomagenesis.2 The Okada lab
recently implemented a trial in which
newly diagnosed children with difuse
FIGURE: 
midline glioma who are positive for
HLA-A2 and the H3.3K27M mutation
that underwent radiation therapy,
received a specifc H3.3K27M peptide
vaccine, combined with the tetanus
toxoid (TT) peptide, emulsified in
Montanide. Poly-ICLC, which is a
Toll-like receptor 3 agonist, was given
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concurrently to improve the thera-
peutic efects of the vaccine. Vaccine
was administered every three weeks
for the first 24 weeks. If there was
stable or improved disease, vaccine
was administered every 6 weeks for a
total treatment period of 96 weeks. My
objective was to develop an immune
evaluation system to gain insight into
immune response to H3.327 peptide
vaccine. Peripheral blood mono-
nuclear cells were obtained at each
of these time points and analyzed
utilizing mass cytometry (CyTOF).
CyTOF is an emerging single-cell
analysis platform that uses atomic
mass spectrometric analysis to quan-
tify up to 42 metal-tagged antibodies
per cell. The large number of analytes
per cell allows the simultaneous moni-
toring of multiple immune subsets
from small tumor samples, making it
ideal for this clinical trial. Dextramer
technology involves utilizing heterog-
enous polymers conjugated to MHC
molecules that bind to T-cells and
can subsequently be detected using
CyTOF. 
Control T-cells and K27M TCR
transduced T-cells were treated with
dasatinib to reduce TCR internaliza-
tion and subsequently stained with cis-
platin. This was followed with staining
with H3.3 dextramer with conjugated
PE fuorophore and metal conjugated
CD3 (141Pr). H3.3 dextramer-PE was
detected on CyTOF using anti-PE
monoclonal or polyclonal antibody
conjugated 173Yb. These preliminary
results indicate that TCR-specifc T
cells can be detected using dextramer-
PE and metal conjugated anti-PE
monoclonal antibody with minimal
non-specifc staining. Furthermore,
this validated the efcacy of utilizing
dasatinib as a method of increasing
TCR cell surface expression. This will
serve as a powerful tool to learn about
how the anti-tumor immune response
could be activated and the impact
of tumor microenvironment on the 
functional status of vaccine-induced
T-cells both systemically and locally. 
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 B
asic Science: 
A M
achine Learning Approach to M
apping Co-regulated 
Variant Loci and Gene Expression over Tim
e 
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M
SII 
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W
ashington 
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of M
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W
e developed a m
achine learning 
analysis pipeline to discover func-
tional gene variants by exam
ining 
the efect of R
N
A
 containing single 
nucleotide variants (SN
Vs) on gene 
expression at cis- and trans- genom
ic 
locations over tim
e. T
his refects a 
hypothesis of genetic co-regulation 
w
here, as the relative presence of a 
particular variant allele seen in R
N
A
 
transcription changes over tim
e 
(due to changing cellular require-
m
ents), gene expression elsew
here 
in the genom
e is afected as a result 
(Figure 1). W
e believe this analysis 
pipeline can give novel m
echanistic 
insights into a w
ide range of basic and 
translational cell biology questions, 
particularly on the evolution of drug 
resistance in cancer cells. 
In order to m
easure changing 
cellular requirem
ents in cancer cell 
lines, w
e conducted paired-end R
N
A
 
sequencing on hum
an m
elanom
a cell 
line W
M
164 under four experim
ental 
conditions: w
ith and w
ithout histone 
deacytelase (H
D
AC
) inhibition, and 
w
ith and w
ithout IFN
-gam
m
a treat-
m
ent. T
his w
as done over eight tim
e 
points each, for a total of 32 sam
ples. 
W
e then aligned the R
N
A
-sequencing 
reads tothehum
an genom
eandcalled 
variants. 1 
M
easuring the regulation of 
variant containing R
N
A
 is a problem
 
FIGU
RE 1:
the H
orvath lab has tackled using a 
novelm
etriccalled theVariantA
llele 
Frequency (VA
F). 2 T
he variant allele 
frequency (VA
F) m
easures the R
N
A
 
expression of SN
V
-containing loci 
(VA
F
 = n
 / ( n
 + n 
)), w
here 
R
N
A
 
var 
var 
ref 
nvar and nref are read counts con-
taining the variant and reference SN
V
 
(Figure 1). W
hereas a D
N
A
 allele 
count can m
odel the efect of a dis-
crete dose of variant harboring alleles 
(N
 ∈
 {0,1,2} for diploid genom
es) on a 
phenotype such as transcription, the 
VA
F is a continuous m
easurem
ent 
w
ith a support of N
 ∈
 [0,1]. T
hus the 
VA
F
accountsforthetrueallelicprev-
alence at m
ulti-allelic loci and refects 
m
olecular regulation events such 
as im
printing, post-transcriptional 
regulation by R
N
A
 binding m
ol-
ecules, as w
ell as R
N
A
 editing. From
 
here, w
e needed to see if tem
poral 
VA
F regulation m
irrored absolute 
gene expression trends elsew
here in 
the genom
e, elucidating functional 
relationships betw
een gene variants 
and gene expression. 
O
ur pipeline starts w
ith clustering 
in G
raphia Professional, w
hich uses 
a graph-based approach to build 
relationships betw
een genes. 3,4 Each 
VA
F or gene expression “tim
e-course” 
groups w
ith another if it m
eets a 
m
inim
um
 Pearson correlation of 
0.96. A
s a result, genes w
ith sim
ilar 
expression trends and VA
F trends 
are connected to each other in a 
structured graph (Figure 2). W
e then 
used a m
achine learning m
ethod 
called the M
arkov C
luster algorithm
 
(M
C
L) to partition the graph into 
form
al clusters by looking for packs 
of highly interconnected genes. 5 W
e 
then built custom
 R
 m
odules to scan 
through the clusters to fnd pairs of 
VA
F and gene expression profles that 
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cluster together in two samples or
more. Once found, each pair was cat-
egorized as a cis- relationship if they
were less than one million base-pairs
apart, and trans- otherwise. 
All 60,963 VAF and gene expres-
sion profles were clustered into 3,730
clusters, where each cluster represents
a certain pattern of RNA regulation
through time. Using custom R scripts,
we discovered 440 co-reg ulated
VAF containing positions and gene
expression profles. Further work will
include Protein-Protein Interaction
(PPI) analyses to validate fndings,
especially in a larger data set.
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Association of SREBF1 and TOM1L2 Polymorphisms with 
Bone and Muscle Phenotypes 
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It is well established that muscle and
bone have a rich and complex biome-
chanical relationship. In particular,
according to the mechanostat hypoth-
esis, bone growth and bone loss are
stimulated by the local mechanical
elastic deformation of bone. Thus,
bone mineral density (BMD) increases
in response to muscle use and strength-
ening due to increased load-bearing of
the afected bone.1 Originally, it was
thought that the strain of the muscle
on the bone was the primary impetus
causing the increased BMD, how-
ever, more recently, researchers have
concluded that a paracrine/endocrine
relationship between muscle and
bone is the more likely explanation.
From the onset of life, muscle and
bone cells are highly similar due to
their common mesodermal origin.2 
At the height of their development, 
these tissues make up the majority of
our body mass and exhibit complex
endocrine relationships with the rest
of the body.3 While the proteins that
are secreted from muscle and bone are
well described, the genetic variants
that infuence these relationships are
not fully understood. In this study,
we focused on two single nucleotide
polymorphisms (SNPs) (rs1889018 and
rs7501812) found in genes SREBF1 and
TOM1L2, respectively. Our goal was
to explore their individual and possible
pleiotropic efects on bone and muscle
phenotypes in one cohort of African
American children (Bone Health) and
two cohorts of young adults (FAMuSS
and AIMMY). 
All cohorts were genotyped using
the Applied Biosystems Taqman
allelic discrimination assays and the
QuantStudio 7 Flex Real-Time PCR
System. After testing for Hardy-
Weinberg equilibrium (HWE), data
was stratified by
to be signifcantly associated with the
muscular phenotypes in each cohort.
This expectation was confirmed
using an additive model in Caucasian
females from the AIMMY cohort for
right hand grip strength; however, this
fnding was not extended to the other
cohorts. TOM1L2 is often studied
in conjunction with SREBF1 as they
share a locus. Our data confrm the
impact that TOM1L2 rs7501812 has on
a variety of phenotypes including total
body BMD, grip strength, VO2 max
and baseline 1-repetition maximum
strength in more than one cohort
and in both Caucasians and African
Americans, thus meeting our expecta-
tions based on the existing literature.
The pleiotropic features of TOM1L2/ 
sex and cohort and The role of SREBF1 has been well described in 
a n a l y z e d u s i n g  
analysis of covari- recent literature as a regulator of myogenic regu-
ance (ANCOVA) 
applying both an latory factors (MRFs) and causes muscle atrophyadditive and domi-
nant model. Where when overexpressed both in vivo and in vitro. appropriate, post
hoc pair-wise com-
parisons were performed and the
resulting p-values adjusted for multiple
comparisons using the Sidak method.
For the SNP-SNP interaction anal-
ysis, linear regression models were
used and included gender, appropriate
covariates, and an interaction term
quantifying the number of minor
alleles present for each SNP pair.
The role of SREBF1 has been well
described in recent literature as a regu-
lator of myogenic regulatory factors
(MRFs) and causes muscle atrophy
when overexpressed both in vivo and
in vitro.4 Based on this finding, we
expected the SREBF1 SNP rs1889018
SREBF1 have been explored in con-
junction with other loci affecting
BMD and lean mass.5 In this study,
we found that the two SNPs had a
statistically significant pleiotropic
relationship with the phenotypes
VO2 max and bone volume of the non-
dominant arm in the FAMuSS cohort,
while the relationship in the dominant
arm approached signifcance. 
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Genetic variants in the muscle-spe-
cific gene FAM210A (rs4796995),
and the bone-specific gene SOST
(rs4792909), which codes for the osteo-
kine sclerostin, have been shown to be
associated with total BMD and frac-
ture risk. FAM210A knockout mice
have low grip strength, as well as high
levels of matrix metalloproteinase-12
(MMP-12), a bone-resorption related
peptide. Sclerostin suppresses the
Wnt/b-catenin signaling pathway in
osteoblasts and osteocytes by binding
to LRP5/6 coreceptors, thereby inhib-
iting osteoblast development. The
purpose of this study is to explore the
infuence of these genetic variants on
musculoskeletal phenotypes in three
previously developed cohorts. 
Cohorts: AIMMY: 153 Caucasian 
young adults aged 18-35 (82 M, 71 F; avg.
age 23.2 yrs) and 75 African American 
young adults aged 19-25 (21 M, 54 F;
avg. age 19.2); FAMuSS: 368 young
adults (135 M, 233 F, avg age 23); Bone 
Health: 73 healthy African-American
children, (38 male, 35 female; ages 5-9)
Phenotypes: AIMMY: right and left 
arm grip strength, maximal oxygen
consumption (VO2 max), and body
mass index (BMI). FAMuSS: base-
line isometric strength and 1-RM
strength in the non-dominant (ND) 
and dominant (D) arms, and total
bone and cortical humeral bone vol-
umes. Bone Health: height-adjusted
tota l BMD minus head z-score.
Genotyping: Applied Biosystems
Taqman allelic discrimination assays 
and the QuantStudio  7 Flex Real-
Time PCR System were used to per-
form genotyping. Statistical Analysis:
Hardy-Weinberg equilibrium was
assessed. Phenotypes were tested
in gender specif ic cohorts using
ANCOVA, where phenotype was
the independent variable, genotype
was the dependent variable, and
weight and/or age were covariates.
Post hoc pair-wise comparisons were 
performed and the resulting p-values 
adjusted using the Sidak method. For 
the SNP-SNP interaction analysis,
linear regression models were used
and included gender, appropriate
covariates, and an interaction term
quantifying the number of minor
alleles present for each SNP pair. IRB:
This project was approved by the IRB
of the Children’s National Health
System and the University of Calgary. 
SOST was found to be out of Hardy-
Weinberg equilibrium in the FAMuSS
(p=0.034), Bone-Health (p=0.006),
and AIMMY cohorts (p<0.001).
Among men of FAMuSS, statistically 
signifcant associations were found
between variants of FAM210A and
D arm baseline bone+marrow volume
(p=0.006), D arm baseline cortical
bone volume (p=0.001), and ND
arm baseline cortical bone volume
(p=0.009) using an additive model.
Statistically signifcant associations 
were found between FAM210A and
the right (p=0.022) and left (p=0.007) 
grip strengths of African-American
women of AIMMY. Caucasian males 
of AIMMY were found to have a
statistically significant association
between VO2 max and FAM210A
in both the additive (p=0.037) and
dominant (p=0.002) models. No
significant association was found
b et we en FA M 210A t he B one -
Hea lt h phenot y pes.  SN P- SN P 
interaction analysis between SOST
and FAM210 showed statistically
signifcant interactions in FAMuSS
on ND arm baseline 1-RM strength 
(coeff icient=0.567, p=0.046) and
N D a rm baseline cortica l bone 
volume (coefcient=352, p=0.040). A 
Continued on p. 16 
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Continued fom p. 15 
statistically significant interaction
was also found in the Caucasian
subgroup of AIMMY in VO2 max
(coefcient=1.529, p=0.037).
Early identifcation of individuals 
at risk for developing lower peak bone
mass and possibly increased fracture 
risk as seniors has the potential to
set the stage for the development of 
personalized medicine protocols/ 
inter ventions designed to reduce
long term fracture risk by helping
these individuals maximize the use
of appropriate ftness, nutrition, and 
other health maintenance strategies. 
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The glioblastoma microenviron-
ment is particularly immunosup-
pressive, including many secreted
and cell-based immune suppres-
sive mecha nisms.1 Progra mmed 
death ligand-1 (PD-L1) is a labile,
inducible transmembrane receptor
ligand that facilitates immune system
evasion through co-ligation of its
receptor, PD-1, on activated T-cells.2 
Figure: Kaplan–Meier survival estimates comparing high and low PD-L1 expression 
in glioblastoma  (A) Differences in survival curves from tumors meeting the 2007 WHO 
histologic criteria for glioblastoma (5% PD-L1 cut-off)  (B) Differences in survival curves from 
recurrent IDH-wildtype glioblastoma reclassifed according to the 2016 WHO nomenclature 
(5% PD-L1 cut-off)  (C) TCGA survival curves, classifed only as glioblastoma, stratifed by 
median PD-L1 mRNA expression  (D) Survival curves from TCGA patients after fltering for 
recurrent, non–G-CIMP (IDH-wildtype) tumors (median PD-L1 mRNA cut-off)  
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Upregulation of PD-L1 on tumor cells
has been proposed as a mechanism of
immune escape in gliomas,3 and its
detection at the protein level has been
previously demonstrated.4,5 However, 
study characteristics (grading, sample
size) and technical considerations
(assays, cut-offs) have resulted in
highly variable rates of expression —
ranging from 6.1% to 88% in larger
studies.4 Furthermore, the role of
PD-L1 as a prognostic marker in
gliomas, independent of predicting
treatment response, remains conten-
tious. A specific cut-off for PD-L1
expression has not been established
in glioblastoma, and it remains to
be seen what role PD-L1 expression
has in patient selection in future
clinical trials which include PD-1/ 
PD-L1 blockade — as either a predic-
tive or prognostic marker. Here, we
sought to address the prognostic role
of PD-L1 in recurrent glioblastoma
in a large tumor cohort according
to the updated 2016 World Health
Organization (WHO) classifcation
of difuse gliomas. Additionally, we
sought to localize cellular expression
of PD-L1 in the tumor microenviron-
ment using multiplex immunofuores-
cence in post-treatment glioblastoma.
Checkpoint inhibition has demon-
strated clinical efcacy in a variety
of solid tumors. Reports of PD-L1
expression in glioblastoma are highly
variable (ranging from 6% to 88%)
and its role as a prognostic marker has
yielded conficting results. To validate
the prevalence and prognostic role of
PD-L1 expression in a large cohort of
difuse gliomas according to the 2016
revised WHO classifcation. Using
tissue microarrays, we compared 5
PD-L1 monoclonal antibodies (n = 56)
and validated expression (n = 183) using
quantitative immunohistochemistry
(IHC) and RNA in situ hybridiza-
tion (RISH). Expression data from
PD-L1 IHC (SP263) N(%) 
Total 
n = 183a 
≥1% n = 54 
(29 5) 
≥5% n = 43 
(23 4) 
≥25% n = 28 
(15 3) 
Age (yr) 
Median (range)  48 (4-75)  52 (4-74)  53 (18-74)  53 (23-74) 
Sex 
Female  57 (31)  16 (30)  14 (33)  6 (21) 
Male  124 (69)  38 (70)  29 (67)  22 (79) 
Presentation 
Primaryb  46 (25)  13 (24)  11 (26)  9 (3) 
Recurrent/post-
therapy 
137 (75)  41 (76)  32 (74)  19 (68) 
Diagnosis (WHO 2016) 
LGG  6 (3 3)  0 (0)  0 (0)  0 (0) 
AA, IDHmut  21 (11 6)  1 (1 8)  0 (0)  0 (0) 
AO, IDH-mut/1p19q 
codeleted 
5 (2 7)  2 (3 7)  1 (2 3)  1 (3 6) 
Glioblastoma, IDHwt  81 (44 2)  37 (68 5)  30 (69 7)  20 (71 4) 
Glioblastoma, IDHmut  13 (7 1)  2 (3 7)  1 (2 3)  0 (0) 
Glioblastoma, NOS  31 (16 9)  12 (22 2)  11 (25 6)  7 (25) 
DMG, H3K27Mmut  16 (8 8)  0 (0)  0 (0)  0 (0) 
TABLE:
LGG, low-grade (diffuse) glioma (WHO grade II); AA, anaplastic astrocytoma; AO,
anaplastic oligodendroglioma; DMG, diffuse midline glioma  
an = 5 cases did not have available clinical information  
bPrior to chemotherapy or radiotherapy  
Glioblastoma, NOS: WHO grade IV diffuse gliomas with negative IDH R132H staining 
and an alternative IDH1 or IDH2 mutation probability between 11 and 89%  
Not shown: AANOS (not otherwise specifed, n = 2); AAIDHwt (n = 1); AOANOS 
(anaplastic oligoastrocytoma, n = 1); AONOS (n = 1); DMG non-H3K27M (n = 5)  
The Cancer Genome Atlas (TCGA)
and published studies were compared
with clinical outcome. Multiplexed
immunophenotyping was used to
identify PD-L1+ cell populations in
post-treatment glioblastoma. Using
a 5% cut-of, PD-L1 expression was
signifcantly associated with a poor
prognosis in both histological ly
defned (n = 125, log-rank P < .001) and
recurrent isocitrate dehydrogenase
(IDH)-wildtype glioblastoma (n = 60,
log-rank P = .015). PD-L1 remained a
signifcant negative prognosticator in
Cox regression analysis (hazard ratio: 
1.96, P = .021). Analysis of TCGA data 
confrmed decreased overall survival
in recurrent non–glioma CpG island
methylator phenotype (G-CIMP)
glioblastoma (n = 12, log-rank P = .023),
but not in glioblastoma as a group (n =
444, log-rank P = .135). PD-L1 RISH
Continued on p. 18 
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Continued fom p. 17 
showed a signifcant correlation with
IHC (P < .0001). PD-L1 was observed
in the proliferating perivascular
stem cell and immune niche of post-
treatment glioblastoma. A 5% PD-L1
expression cut-of identifed a subset
of glioblastoma that is associated with
a worse clinical outcome. This asso-
ciation remained signifcant within
the newly defned IDH-wildtype clas-
sifcation. These fndings could have
implications for patient stratifcation
in future clinical trials of PD-1/PD-L1
blockade. 
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Hidradenitis suppurativa (HS) is
a chronic inf lammatory disease of
the skin which classically presents
as recurrent painful and exudative
lesions most often found in inter-
triginous areas with high densities
of apocrine glands. HS prevalence
is estimated between 0.05% and
4.10% of the population; however, its
morbidity can be signifcant due to
the debilitating nature of the lesions
and the social stigma associated with
purulent and malodorous discharge.1 
While the exact pathophysiology of 
HS is not known, the NOTCH sig-
naling pathway involved in embryo-
logic development, cell diferentiation,
and molecular signaling has previously
been implicated without identifcation
of exact genes.2,3 This study aims to
evaluate the cytoarchitecture, cell sur-
face markers, and molecular signaling
pathways present in HS patients to
further understand the disease and
identify potential therapeutic targets
to ultimately provide an alternative to
surgical excision. 
Samples were obtained from 11
patients with HS who underwent
surgica l excision and compared 
to 11 samples of normal skin (NS).
Histopathology of HS and NS samples
were compared via hematoxylin and 
eosin (H&E) staining and imaging at
10x magnifcation.
Anti-CD3, a T-cell marker, and
anti-CD31, a PECAM and vascular
T-cell specifc marker, were used for
immunohistochemical (IHC) analysis.
IHC was conducted in four HS and
four healthy skin specimens with six
regions of interest (three epidermal
and three dermal) per sample.  Cellular
quantifcation was performed at 40x
magnification and compared with
Student’s t-test. 
Finally, RNA was extracted and
quantifed, and cDNA was generated
via reverse transcriptase PCR from
3 NS and 4 HS biopsies. A NOTCH
signaling PCR array was used to
identify the degree of gene regulation.
Candidate genes were identified if
their fold change was greater than or
less than 2.5 when compared to normal
skin in at least three of the HS samples.
Histopathologic examination
showed that HS skin had wider epi-
dermal layers, extending into and
engulfng the dermis, as well as exten-
sive dermal cellular infltration and 
aggregation. IHC analysis revealed
that, at the dermal level, HS lesions
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had a signifcantly greater quantity of
CD3+ (324.29±139.28 vs. 14.93±16.32,
p<0.0001), and CD31+ (322.15±155.46
vs. 2.84±5.56, p<0.0001) cells/mm2
than healthy skin samples (Table). 
NOTCH array analysis identi-
fed three genes in HS with a 2.5-fold
upregulation compared to NS: KRT1
(keratin family), UbD (ubiquitin
D), and CCNE1 (cyclin-dependent
kinase). Ten genes were down-regu-
lated in HS more than 2.5-fold com-
pared to NS: CCND1 (cyclin D1
regulator of G1/S transition), Hey1
(involved in somite development),
MFNG (demarcates boundaries 
during embryological development), 
MMP7 (metalloproteinase involved 
in tissue remodeling), Notch 4 (cell
proliferation and differentiation),
DLL4 (encodes for NOTCH ligand),
LFNG (defines boundaries during
embryological development), PPAR-g
(adipocyte diferentiation), and LMO2
(yolk sac erythropoiesis). 
Epidermal and dermal cytoarchi-
tecture of HS lesions difer in com-
parison to healthy skin with HS lesions
Immunohistochemical Identifcation and Quantifcation of
Cells in Hidradenitis Suppurativa vs. Normal Skin 
Skin Type CD3 CD31 
Epidermis 
(n=12) 
Dermis (n=12) 
Epidermis 
(n=12) 
Dermis (n=12) 
“Hidradenitis
Suppurativa
(cells/mm2±SD)” 
2 28±5 46 324 29±139 28 4 27±7 72 322 15±155 46
“Normal 
(cells/mm2±SD)” 
6 40±10 37 14 93±16 32 2 84±4 20 2 84±5 56 
p-Value 0 2123 <0 0001 0 5806 <0 0001 
TABLE:
demonstrating a signifcantly greater
dermal lymphocytic infltrate com-
pared to healthy skin. Additionally,
genes involved in embryological devel-
opment as well as skin and adipocyte
differentiation are dysregulated in
HS. Work is ongoing to correlate the
identifed candidate genes with their
respective protein levels by IHC with
the goal of identifying molecular tar-
gets for treatment of HS. 
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Cancers exhibit altered DNA meth-
ylation compared to normal cells,
including decreased methylation at
regions normally silenced for genome 
stability and increased methylation
at promoter regions of tumor sup-
pressors. 5-azacytidine (Aza) is a
DNA methyltransferase inhibitor
(DNMTi) that removes DNA meth-
ylation and is FDA approved for the 
treatment of myelodysplastic syn-
drome. We have shown that DNMTi 
upregulate the interferon response,
tumor antigens, and antigen presenta-
tion in solid tumors, contributing to 
an overall upregulation in immune sig-
naling.1 DNMTi activate a canonical 
interferon signaling pathway through
upregulated expression of dsRNA,
specifcally hypermethylated endog-
enous retroviruses (ERVs) that acti-
vate dsRNA sensors. The interferon 
response activated by ERV signaling 
recruits immune cells, promoting
tumor clearance and sensitization to 
immune therapy.2 
We sought to determine whether
DNMTis cause a similar ERV acti-
vation and cell kil ling in B - and
T-cell malignancies, focusing frst on 
mantle cell lymphoma (MCL). We
FIGURE 1: Dose response curve for AZA treatment  
further hypothesized that mutations 
in ten-eleven translocation methylcy-
tosine dioxygenases (TET), enzymes 
that normally demethylate DNA,
might lead to a hypermethylated
state making cells more resistant to
direct cytotoxicity from DNMTis.
We also sought to test the efects of 
TET mutation on ERV induction
and immunogenicity. For 5-Aza to
inactivate DNMTis it must be incor-
porated into the DNA of actively
dividing cells. Since Aza is only stable 
in the body for <30 minutes and MCL 
cells have slow doubling times, only a 
fraction of cells divide during that 30 
minute window. To improve response
in these cancers, extended drug avail-
ability is necessary. 
We used three different treat-
ment regimens to demonstrate that
extending the availability of active
drug shows a better response, sig-
nificantly more so than increasing
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the drug dose or treating for a longer 
period of time. The treatments
included: one dose a day for 3 days (3 
Day Tx; blue), one dose a day for 5 days
(5 Day Tx; red), and three doses a day 
for three days (3X3 Tx; green). This
was done for a dose response curve
of 250, 500, 1000, 2000, and 4000
ηg/mL, compared to PBS control (0). 
Figure 1 shows the percentage of live 
cells at two time points, day 6 and 9 
after starting treatment. In the TET 
wild type MCL cells (Maver, Mino,
Jeko) the 3X3 group showed better
killing when compared to 3- and
5-day Tx. The differences between
the 3X3 treatment and the single
dose per day was more pronounced in 
the slowest growing cell lines. Mino, 
which showed the largest diference
in killing, doubles between 50-72hrs, 
whereas Jeko (doubling time 26-33hrs)
shows a less drastic diference between
the 3 dose versus 1 dose per day groups.
This supports the hypothesis that
slower growing tumors beneft from 
sustained drug delivery over increased
drug dose. TET mutated leukemia
cells (Karpas299, CCRF-CEM), were
less Aza sensitive. This supports our 
hypothesis that TET mutations lead 
to a hypermethylated state more
resistant to DNMTi. The resistance 
correlates with the extent of TET
mutations. Karpas, the most resis-
tant, has mutations in TET1 and
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TET2, whereas CCRF only has TET3 
mutated. In vivo responses by these
tumors to DNMTi is likely due to
increased immunogenicity, rather
than just direct cytotoxicity, which 
is supported by the increase in ERV 
expression shown in Figure 2 (ERVs 
profiled: Syncytin-1, ervFC2, and
envW2). CCRF showed increased
ERV expression in both the fve-day 
treatment and the 3X3 treatment. 
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The brain uses glucose and related
substrates for energy (Berg et al., 2002)
but how the brain transports and uses
glucose during development has not 
been completely characterized. The
aim of this project is to compile an
age, region- and cell-specifc profle
of glucose transport and utilization
during development using a mouse
model. This profile can be used to
better understand metabolic changes
in pediatric diseases such as perinatal 
hypoxia, epilepsy, hyperglycemia, and
mitochondrial disease. 
Brains of C57Bl/6 mice were 
har vested and dissected at ages
P11, P15, and P30, corresponding
to neonates, young children, and
adolescents respectively. The frontal 
cortex, hippocampus, and white
matter were isolated by micro-
dissection, each having diferent cell 
populations important in learning,
memory, and cognition during early
development. Glucose transporters
(GLUT) 1, 2, 3, 4, and 8 were selected 
as measures of brain glucose transport
(Gomez et al., 2010) and quantifed via
Western Blotting. 
GLUT1 is in the blood-brain bar-
rier endothelium (Sankar et al., 2002).
As vascularization is established early,
we did not expect signifcant changes 
in GLUT1 expression during develop-
ment, and no signifcant diference
FIGURE 1: Western Blot of GLUT2 levels in the frontal cortex (FC), hippocampus 
(H), and white matter (WM) of P11, P15, and P30 mouse brains (top) Western 
Blot quantifcation of GLUT2 levels, expressed as ratio to actin in the frontal cortex,
hippocampus, and white matter of P11, P15, and P30 mouse brains (N = 3) (bottom)  
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between ages in the frontal cortex was
seen (Figure 1). 
GLUT2 is preferentially expressed
in astrocytes (Qutub and Hunt, 2005).
As the number of astrocytes increases
with age (Reemst et al., 2016), we
expected an increase in GLUT2
expression during development, espe-
cially in the hippocampus (Oberheim 
et al., 2012). GLUT2 expression was
signifcantly increased by P30 in the 
frontal cortex and (Figure 2) and
there was no signifcant diference in 
GLUT2 expression in white matter. 
GLUT3 is the main glucose trans-
porter in neurons (Gomez et al.,
2010), but there is little temporal and 
no region-specific data for GLUT3
expression. Results showed no statis-
tically signifcant changes in GLUT3 
expression in the hippocampus and
white matter and a mild statistically 
insignificant upward trend in the
frontal cortex. The lack of statistical 
significance may be that the peak
expression occurs between the ages
we analyzed and was not detected. 
GLUT4 and GLUT8 are both
insulin-dependent glucose trans-
porters (Sankar et al., 2002).  An
upward trend in GLUT4 expression
by P30 was seen, but no signifcance 
in the frontal cortex, hippocampus, or
white matter was seen. There was very
high variability among individuals.
GLUT 8 expression, however, showed
an extremely signifcant increase in
P30 mice in the frontal cortex, hip-
pocampus, and white matter, which
can be explained by the feeding pat-
tern of mice. From birth until P15,
the mice are in their suckling phase 
and receive mostly proteins and fatty 
acids through their mothers’ milk
(McKenna et al., 2015) but by P30
mice feed on their own and have a
diet rich in carbohydrates, which
stimulates insulin release. Since
GLUT8 is an insulin-dependent
glucose transporter, the increase in
insulin should cause an increase in
expression of GLUT8 in the brain.
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Although GLUT4 should have shown
similar patterns in expression, it is
only weakly expressed in the brain.
Therefore, GLUT8 may be the key
insulin-dependent glucose trans-
porter in the brain. Links to metabolic
changes in diabetic pediatric patients
should be further explored. 
Future studies include immunos-
taining human brain from a neonate, 
a young child, and an adolescent. Mice
subjected to perinatal hypoxia will
be compared to this profle to better 
understand the metabolic changes
that occur in this common pediatric 
form of brain injury. 
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FIGURE 2: Western Blot of GLUT8 levels in the frontal cortex (FC), hippocampus 
(H), and white matter (WM) of P11, P15, and P30 mouse brains (top) Western 
Blot quantifcation of GLUT8 levels, expressed as ratio to actin in the frontal cortex,
hippocampus, and white matter of P11, P15, and P30 mouse brains (N = 3) (bottom)  
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Osteoporosis is a signifcant burden
for our aging population. Developing 
a better understanding of the genetic 
underpinnings of poor bone quality
may assist in the future development 
of prevention strategies. A study by
Correa-Rodriguez (2016) identifed a 
group of single nucleotide polymor-
phisms (SNPs) that were associated
with both body composition and bone
mineral density (BMD) in a popula-
tion of Caucasian young adults.1 In 
particular, they found rs3736228 in
the low-density lipoprotein receptor 
related protein 5 (LRP5) gene par-
ticularly inf luenced BMD. SNP
rs3736228 has been demonstrated to
have a pleiotropic efect on pheno-
types, demonstrating associations
in other studies with body composi-
tion, circulating nutrient levels, and
obesity.2,3,4 The aim of this study
Characteristic 
Females Males 
N Mean ± SD N Mean ± SD 
Age (years) 96 22 3 ± 4 4 93 23 7 ± 4 2 
Weight (kg) 96 62 4 ± 9 2 93 78 0 ± 12 3 
Height (cm) 96 165 9 ± 5 8 93 178 8 ± 7 7 
BMI 96 22 7 ± 2 9 93 24 3 ± 3 1 
TABLE: AIMMY Demographics 
is to expand existing knowledge of
LRP5 and explore the association of 
rs3736228 polymorphisms and BMD 
to replicate the fndings of previous
studies regarding the association of
SNP rs3736228 with BMD in a cohort 
of healthy young adults. 
Participants from the University
of Calgary cohort from the Assessing 
In herited Metabol ic Sy nd rome 
Markers in the Young (UC AIMMY)
study included 209 healthy young
adults and mixed ethnicity, pre-
dominantly Caucasian (81%) young
adults (male n=102, female n =107,
average age=23 years). Phenotypes
were height, weight, body mass index 
(BMI), and total BMD. Genotyping: 
Allelic discrimination was deter-
mined using Applied Biosystems
Taqman and Applied Biosystems
7900HT Realtime PCR. Statistical
Analysis, after being tested for Hardy-
Weinberg equilibrium (HWE), the
data was stratified by sex and ana-
lyzed using analysis of covariance
(ANCOVA) and a dominant model.
Where the f-tests were signifcant,
post hoc pairwise comparisons were 
performed and the resulting p-values 
were adjusted for multiple comparison
using the Sidak method. 
The genotype distribution for
rs3736228 in the AIMMY cohort was
found to be in HWE. Using a domi-
nant model, we found that females
with one or more copies of the risk
T allele had a signifcant lower mean
total BMD (CC: n=69, 1.129 ± 0.010;
CT/TT n=29, 1.089 ± 0.016; p = 0.0347).
However, a similar association was
not seen in males. No signifcant asso-
ciations were observed with height,
weight, or BMI. 
The rs3736228 polymorphism
within the LRP5 gene was found to
be negatively associated with BMD
in females in the UC AIMMY cohort.
It is known that the polymorphism
rs3736228 alters the codon in posi-
tion 1330. The more common C allele
encodes alanine, while the minor T
allele encodes valine. This mutation 
downregulates the LRP5 cell surface
receptor function, which plays a
pivotal role in bone formation. The
LRP5 gene has now been shown in
multiple studies to be associated with
bone quality measures like calcaneal
Quantitative Ultrasound (QUS) and
BMD. Our study has expanded these
fndings and suggests that rs3736228
also infuences BMD in healthy young
females. This supports the work
of a recent study which found that
when stratifying by sex, females only
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showed a trend towards signifcance
in calcaneal QUS measures.1 While 
the development of BMD is polygenic,
our work suggests that focus on LRP5
polymorphisms may be particularly
helpful in defining genetic risk for
low BMD. In addition, given that
this polymorphism has shown to have
pleiotropic efects, we plan to investi-
gate the associations of rs3736228 with
other anthropomorphic phenotypes. 
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polymorphism in the LRP5 gene is associ-
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Flores RM, Castro-Hernandez C, Rubio-
Lightbourn J, Velazquez-Cruz R, et al.
Association of LRP5 haplotypes with
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Previous studies have identif ied
specifc genetic loci associated with
variation in bone mineral density
(BMD) in genome-wide association
analyses.1,2 One region in chromosome
2p22-25 was found to have signifcant 
association with BMD variations in
the lumbar spine.3 Growth Regulation
by Estrogen in Breast Cancer 1 gene 
(GREB1), a gene within this loci, was 
recently shown to be upregulated
during osteoblast and chondroblast 
diferentiation.4 In one study, genetic 
variants of GREB1 were found to be 
associated with BMD variations at
the lumbar spine and femoral neck
in Caucasian adults, establishing
GREB1 as a target gene for future
BMD genetic studies.5 The current
study sought to elucidate the role of 
genetic variation in GREB1, specif-
cally polymorphisms rs5020877 and
rs10929757, on BMD measures in a
cohort of African American children 
as well as two cohorts of Caucasian
young adults. 
The relationship between GREB1
polymorphisms and phenotype were 
assessed in three distinct cohorts: Bone
Health, 73 healthy African American 
children previously recruited to assess
fracture risk factors; Functional
Single Nucleotide Polymorphism
Associated with Human Muscle
Size and Strength (FAMuSS), 368
hea lthy Caucasian young adults
previously recruited as part of a
3-month long program to evaluate
Continued on p. 26 
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genetic infuences on strengthening
muscles in the non-dominant arm;
and Assessing Inherited Markers of
Metabolic Syndrome in the Young
(AIMMY ), 153 health Caucasian
young adults and 75 healthy African
American young adults previously
recruited to identify signifcant risk
factors for metabolic syndrome.
The Applied Biosystems Taqman
Allelic Discrimination Assays and
Real-Time PCR system were used
to genotype the DNA samples from 
the cohorts. All statistical analyses
were performed separately by gender, 
and Hardy-Weinberg Equilibrium
(HWE) was assessed for each SNP
in race-specifc cohorts. Analysis of
covariance (ANCOVA) tests were
utilized, where the respective covari-
ates were entered into the model.
Post hoc pair-wise comparisons were 
performed, and the resulting p-values
adjusted for multiple comparisons
using the Sidak method. 
Both SNPs were found to be in
HWE in the FAMuSS and AIMMY 
cohorts, but neither was in HWE
in the Bone-Health cohort. In the
Bone Health cohort, rs5020877 was
significantly correlated with Dual
X-Ray Absorptiometr y ( DEX A)
bone mineral content (BMC) in the
lumbar spine in males (p=0.036) as
well as left hip (p=0.036); whereas,
in females, rs10929757 was signifi-
cantly associated with total body
BMD (p=0.016), as well as BMD for 
the left hip (p<0.001), lumbar spine
(p=0.036), and total body (p=0.035).
In the FAMuSS cohort, rs5020877
genotype was significantly associ-
ated with baseline one-rep maximum 
(1-RM) strength in the non-dominant
(ND) arms of females (p=0.021). In
the AIMMY cohort, neither SNP
Covariates 
used 
Sex rs5020877 rs10929757 
Baseline isometric strength — 
Non-dominant arm 
Age, weight 
F 0 14 0 13 
M 0 35 0 41 
Baseline isometric strength — 
Dominant arm 
Age, weight 
F 0 15 0 3 
M 0 32 0 33 
Baseline 1-RM strength — 
Non-dominant arm 
Age, weight 
F 0 021 0 43 
M 0 19 0 61 
Baseline 1-RM strength — 
Dominant arm 
Age, weight 
F 0 11 0 48 
M 0 29 0 42 
Baseline bone (+ marrow) 
volume — Dominant arm 
Age, weight 
F 0 32 0 48 
M 0 66 0 7 
Baseline bone (+ marrow) 
volume — Non-dominant arm 
Age, weight 
F 0 11 0 44 
M 0 71 0 87 
Baseline cortical bone volume 
— Dominant arm 
Age, weight 
F 0 44 0 26 
M 0 61 0 94 
Baseline cortical bone volume 
— Non-dominant arm 
Age, weight 
F 0 051 0 33 
M 0 69 0 53 
TABLE: Phenotype Analysis for GREB1 Polymorphisms in the FAMuSS Cohort 
showed a signifcant association with 
any phenotype. There were no signif-
cant SNP-SNP interactions between 
rs5020877 and rs10929757 for any of
the phenotypes analyzed. 
The results from this study dem-
onstrate that variations in the GREB1
gene, originally known for its role in 
tumor progression and more recently 
for its role in osteoblast/chondroblast 
diferentiation, may contribute to dif-
ferences in baseline 1-RM strength of 
dominant and non-dominant arms,
lumbar spine BMC as well as total
body, left hip, and lumbar spine BMD.
These fndings suggest independent
effects of these two loci and that
patients with rare allele for rs5020877 
are stronger but have decreased bone 
quality while those with the rare allele
for rs10929757 have an increased bone
quality. However, given the small
number of patients having the rare
allele for either SNP, further study is 
needed to verify these fndings. 
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There is a pronounced onco-racial
disparity in Washington, D.C., which
had the highest national incidence of 
breast cancer in African American
patients between 2010 and 2015 and
the worst outcomes.1 Recent data 
indicates a higher incidence of delete-
rious BRCA1 [and BRCA2] mutations
and variants of uncertain signifcance
(VUS) in African American patients 
compared to Caucasian patients when
controlling for patients of Ashkenazi 
Jewish (AJ) descent.2 Despite this,
African American women meeting
National Comprehensive Cancer
Network (NCCN) criteria for genetic
testing are less likely to complete
such testing compared to Caucasian 
women nationally.3 Studies have
investigated psycho-social drivers of 
minority patient aversion to genetic
testing. We hypothesize that lack of 
physician referral for cancer genetic
counseling and testing for African
FIGURE 1: Physician referral rates for breast cancer patients treated at GW Cancer 
Center between 2014 and 2018 meeting NCCN criteria differed signifcantly by race 
(BNH 76 5%, N = 88 and WNH 92 7%, N=127; χ2=13 0642, p-value=0 00030 
(p-value signifcance <0 05)  
Not 
Referred 
Referred 
20 0 60 40 100 80 140 120 
27 
10 
127 
88 
Numer of Individuals 
■ non-Hispanic African Americans ■  non-Hispanic Caucasians 
American women contributes to this 
disparity. 
A total of 1,180 patients (non-
Hispanic African Americans (BNH) 
N=502; non-Hispanic whites (WNH)
N=435) were treated at the George
Washington Cancer Center (GW
Cancer Center) for breast cancer
(both in situ and invasive carcinoma), 
between 2014 and 2018. Utilizing GW
Cancer Center’s Cancer Registry, we 
identifed women by race (BNH N
=115; WNH N =137) who met select
NCCN criteria for referral for genetic
evaluation including breast cancer
diagnosis under age 50, triple nega-
tive breast cancer (TNBC) under age 
60, and two primary breast cancers.
Excluded patients were those who
were not BNH or WNH or who did 
not meet the select NCCN criteria
listed above. Patients were then
stratifed by race according to who
underwent genetic evaluation (BNH
N= 81, WNH N= 116), whether at
our Ruth Paul Cancer Genetics and
Prevention Service (RPCGPS) or
elsewhere, by reviewing GW Cancer 
Center records, RPCGPS records,
and patient clinic records for genetic 
screening results from outside insti-
tutions. Patient charts were used to
identify individuals who received a
physician referral during the course
of their cancer care. 
Twenty-one percent of breast
cancer patients seen in GW Cancer
Center between 2014–18 met study
criteria for referral for genetic evalu-
ation (n = 252; BNH N=115, WNH
N=137), including breast cancer diag-
nosis under age 50 (BNH N = 76;
WNH N = 108), TNBC under age
60 (BNH N =14; WNH N =5), and
two primary breast cancers (BNH N 
= 18, WNH N = 16). Several patients 
Continued on p. 28 
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identifed met two or more criteria
for referral (BNH N = 7, WNH N = 
8). Physician referral rates differed
significantly by race (BNH 76.5%,
N = 88 and WNH 92.7%; N= 127; χ2 
=13.0642, p-value=0.00030) (Figure
1). There was no significant differ-
ence in adherence by race for patients 
referred to genetic counseling (BNH 
92%, N=83; WNH= 91%, N=123, χ2 
=0.00178, p-value=0.894) (Figure 2). 
Low genetic testing rates for
African American breast cancer
patients a re a n i mped iment to 
resolving the prominent onco-racial
breast cancer disparities, particularly 
in young, TNBC, and patients with
multiple primary tumors. This study 
identifed a race-based phenomenon 
in physician referral rates. Possible
reasons for this discrepancy may
include lag in physician education on 
the topic of hereditary risk, barriers 
in physician-patient communication
and/or implicit bias. Future work
is needed to clarify the root cause
Not 
Evaluated 
Evaluated 
123 
0 20 40 60 80 100 120 140 
Numer of Individuals 
■ non-Hispanic African Americans ■  non-Hispanic Caucasians 
FIGURE 2: Individual patients treated for breast cancer at GW Cancer Center between 
2014 and 2018 who met NCCN criteria for referral and were referred by their physician 
for genetic counseling stratifed by race and referral adherence 
in order to increase the identifica- 2. Hall MJ, Reid JE, Burbidge LA, et al.
BRCA1 and BRCA2 mutations in women tion of at-risk women in the African 
of diferent ethnicities undergoing testingAmerican community. 
for hereditar y breast-ovarian cancer.
Cancer 2009; 115(10):2222-23. REFERENCES: 
1. Cancer Facts and Figures: 2018. Atlanta, 3. Jones T, McCarthy AM, Kim Y, et al.
GA: The American Cancer Society, 2018. Predictors of BRCA1/2 genetic testing
(Accessed July 4, 2018, at https://www. among black women with breast cancer:
cancer.org/content/dam/cancer-org/ a population study. Cancer Med. 2017;
research/cancer-facts-and-statistics/ 6(7):1787-1789. 
annual-cancer-facts-and-fgures/2018/ 
cancer-facts-and-fgures-2018.pdf.) 
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We sought to determine the utiliza-
tion of otolaryngology and speech-
language pathology services among
infants following open cardiothoracic
procedures. Given their susceptibility
to iatrogenic-induced vocal cord
dysfunction, the proper use of ancil-
lary services is critical in limiting
long-term swallowing and speech
complications. 
A fourteen-month retrospective
review of the Society of Thoracic
Surgeons database at a single tertiary 
children’s hospital was performed to 
include all infants undergoing open
cardiothoracic surgery. Demographic,
operative, and outcome variables were
identifed. 
Our results showed, 67 patients
were identifed (36M/31F; mean [SD] 
gestational age 36.5 [4.5] weeks) whose
surgeries included patent ductus
arteriosus ligation (n=20), aortic
operation (n=10), Tetralogy of Fallot 
repair (n=8), and Norwood proce-
dure (n=6). Post-operatively, 20/67
patients (30%) had documented weak
cry or weak cough; of these, 10 were 
evaluated by otolaryngology, and
seven were found to have vocal cord 
paralysis. 30/67 patients (45%) had
post-operative feeding difficulties,
and 13 had documented aspiration.
Of the 13 with aspiration, fve under-
went a modifed barium swallow with 
speech-language pathology, and fve
had otolaryngology consultations.
On discharge, 13/67 patients (19%)
necessitated gastrostomy tube place-
ment, and 8/67 patients (12%) required
supplemental oxygen or continued
ventilation. Following discharge, 8/67
patients (12%) were followed by oto-
laryngology for vocal cord paralysis
(n=7), persistent dysphagia (n=3), or
stridor (n=2). 
Open cardiothoracic surgery in
infancy is associated with high rates 
of voice and swallowing dysfunction. 
Inpatient ancillary services are under-
utilized in managing this population, 
and outpatient follow-up is poor,
suggesting the need for prospective
protocols to ensure adequate care. 
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The anterior cruciate ligament (ACL)
is one of the most commonly injured 
knee ligaments which requires exten-
sive rehabilitation. Athletes who
injure their ACL risk long-term
disability compromising general
function, including increased rates
of osteoarthritis. Roughly 80% of
ACL injuries have a noncontact
origin, suggesting that ACL injury
risk is greatly infuenced by patterns 
of motion.1 The potential beneft of 
prospectively identifying diferences 
in landing strategies has prompted
the development of ACL injur y-
prevention programs utilizing biome-
chanical interventions, which correct
hazardous movement abnormalities
and reduce rates of injury.2 Studies
have identifed specifc movements,
such as excessive internal rotation
angles at the hip and knee, as placing 
individuals at greater risks for ACL
injury. To detect these abnormali-
ties, motion capture technologies are 
Continued on p. 30 
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employed, but they are often expen-
sive, labor-intensive, and impractical 
screening tools in clinic.3 The depth 
camera in the Microsoft Kinect 2
system has emerged to be a promising
low-cost assessment system that uti-
lizes surface mapping technology to 
generate high-quality human kine-
matic profiles. It maps surfaces by
sending out bursts of infrared light,
which provide real-time tracking
of human limbs.4 This study seeks
to evaluate knee kinematics in the
controls, ipsilateral, and contralateral
leg of ACL reconstructed patients to 
assess ACL injury risk. 
A cross-sectional study of ACL
reconstructed patients at 6 months
post-operation (n=15) and controls
(n=12) was performed. Participants
performed three single leg squats for 
each leg with arms spread out and
opposite leg forward, with move-
ment captured via the Microsoft
Kinect 2 camera placed 1-2 meters
in front of the participant. Custom
MATLAB software was utilized to
analyze raw data, which included hip 
internal rotation (IR), adduction, and
knee fexion at the highest point of
flexion. Negative values for hip IR
corresponded to hip external rota-
tion. Statistics comparing control,
contralateral, and ipsilateral legs were
conducted using one-way analysis
of variance and student T-test, with
signifcance set at p < 0.05. 
The mean age in years was 27.7 and
31.2 for the control and ACL recon-
structed groups, respectively. The per-
centage of females was 17% and 51% 
for control and ACL reconstructed
groups, respectively. For degree of hip
IR, the contralateral group (7.74) was 
signifcantly higher than those of the 
ipsilateral (-2.06; p<0.05) and control 
group (-1.94; p<0.05). There was no
FIGURE 1: Bar graph comparing 
knee fexion across all groups 
* 
120 
100 
80 
60 
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85 5 
Contralateral 
64 7 
signifcant diference in hip adduc-
tion among all groups. Comparing
knee fexion, controls (85.5) had sig-
nifcantly higher degrees of fexion
compared to reconstructed (55.4;
p<0.01) knees. 
At the greatest point of fexion,
the contralateral leg in the ACL group
demonstrated significantly more
internal rotation during a single leg
squat, thereby indicating that the
knee control in the contralateral
leg is abnormal. Rehabilitation may
have improved deficiencies in the
reconstructed knee while abnormal
mechanics on the contralateral side
may further predispose patients to
injury on that side. While not signif-
cant, ipsilateral knees had higher hip 
adduction than that of contralateral 
and control knees. This could also
be used as a motion analysis marker 
for abnormal reinjury biomechanics. 
The depth camera accurately quanti-
fed that ACL patients cannot reach 
the same knee fexion as controls in 
both the ipsilateral and contralateral 
leg; instead, ACL patients performed 
abnormal compensatory behaviors
that further increased risk of re-
injury. Therefore, this prevention-
focused motion analysis system has
emerged as a fast, low-cost, and
non-invasive method to assess lower 
10 
* * 
8 
6 
4 
2 
0 
-2 
-4 
Hip IR Hip Abduction 
■ Reconstructed ■ Contralateral
■ Control 
FIGURE 2: Bar graph comparing 
hip IR, hip abduction across all 
groups  Negative values for hip IR 
correspond to external rotation  
extremity biomechanics with great
research and clinical utility. 
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Trends in Treatment Strategies and Comparison of
Outcomes in Lymph Node Positive Bladder Cancer 
Christina 
Darwish, MSII
Treatment Group ADVISERS:
Surgery Alone (SA) Andrew Sparks,2 
MS; Richard Amdur, Neoadjuvent Chemotherapy (NAC) 1 0 
PhD; 1,2 and Michael Adjuvent Chemotherapy (AC) 
Whalen, MD 1,2 Chemotherapy + Radiation (C+R) 
0 8 
+Censored 
Median Survival (95% CI) 
11 93 (10 48–13 90) 
28 06 (24 48–31 54) 
25 56 (22 74–28 68) 
13 93 (12 00–17 94) 
1 The George Washington University (GW) 
School of Medicine and Health Sciences 
2 GW Medical Faculty Associates 
Chemotherapy Only (C) 13 01 (11 37–14 85) 
No Treatment/Palliative Care (NT) 2 96 (2 27–4 70) 
While extensive research has assessed
treatment outcomes in muscle invasive
bladder cancer, lymph node positive 
disease (LN+) has been excluded from
randomized studies or grouped with 
metastatic disease.1-3 Although node 
positivity confers reduced 5-year
cancer specifc and overall survival, it 
is potentially curable if treated before
systemic metastasis.4 Treatment is
not standardized, however, especially
with lack of radiographic response
to induction chemotherapy.5 This 
study seeks to compare outcomes and
demonstrate trends in treatment for 
LN+ bladder cancer. 
We performed a retrospective
cohort study using the National
Cancer Database (2006-2014) and
identifed 1869 cT2-4N1-3M0 bladder 
cancer patients treated with (1) radical
cystectomy (RC), (2) neoadjuvant che-
motherapy (NAC) + RC, (3) adjuvant 
chemotherapy (AC) + RC, (4) radiation
+ chemotherapy, (5) chemotherapy
alone, or (6) no treatment/palliative
care only. The primary outcome was 
survival by treatment, analyzed using 
Kaplan-Meier and multivariable
Cox-proportional hazards regression.
Secondary outcomes included patho-
logic down-staging, analyzed using
univariable/multivariable logistic
Su
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regression models. A univariable
logistic regression model of treatment
by year was used to identify treat-
ment trends over time. Multivariable 
models were adjusted for confounding
demographic, facility-level, and clini-
copathologic variables.
Among 1869 patients (cN1, 48%;
cN2, 44%; cN3 8%), 567 underwent
RC , 4 18 u nder went NAC , 591  
u nd er w ent  AC ,  61  u nd er w ent 
rad iat ion + chemot herapy,  13 6 
under went chemotherapy alone,
and 96 had no defnitive treatment.
Overall survival did not difer between
NAC and AC, but both had improved
survival compared to RC alone. All
other treatment groups had worse
survival outcomes in comparison to
NAC. When comparing NAC to RC 
alone, down-staging to pT0 (adjusted 
odds ratio [aOR]=26.39) and pN0
(aOR=6.88) was higher for NAC.
Overall, utilization of NAC and no
treatment has increased, use of AC
and RC alone has declined, and use of 
chemotherapy and radiation without
surgery has not changed signifcantly. 
Combined chemotherapy and RC 
is associated with improved outcomes
for LN+ bladder cancer compared to 
RC or chemotherapy alone, although 
there is no significant difference
between NAC and AC. Use of radia-
tion and chemotherapy without RC
has stayed consistent and is associ-
ated with worse oncologic outcomes 
compared to RC with perioperative
chemotherapy, but there is no signif-
cant diference when compared to RC
or chemotherapy alone.
Continued on p. 32 
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Impact of Smoking on Outcomes Following 
Knee and Shoulder Arthroscopy 
Dana Perim,
MSIII
ADVISERS: Jessica 
Hyer, MD, PGY3,
Richard Amdur,PhD,
and Rajeev 
Pandarinath, MD
The George Washington University School of
Medicine and Health Sciences 
With well over a million procedures 
performed annually,1 arthroscopy
of the knee and shoulder are two
of the most commonly performed
orthopaedic surgeries. Optimization
of patient outcomes by minimizing
modifable risk factors is crucial, and 
one well-established modifable risk
factor is smoking. Approximately
15.5% of Americans smoke,2 and the
prevalence of smoking is highest in
males ages 25-64,3 a group which also 
encompasses the majority of patients 
undergoing arthroscopic procedures.1 
The frst step towards mitigating 
the risk associated with smoking is to 
defne its impact on postoperative out-
comes. The purpose of this study was 
to evaluate any association between
preoperative smoking and periopera-
tive and early postoperative complica-
tions in a large population following 
Procedure aOR for smokers 
vs non-smokers 
Lower 95% CI Upper 95% CI p 
KAM 1 228 0 979 1 541 0 08 
SHADEC 1 462 1 03 2 075 0 033 
KAC 1 058 0 703 1 592 0 79 
KAA 1 213 0 859 1 713 0 27 
KAB 1 969 1 407 2 757 < 0001 
DCSA 1 137 0 686 1 883 0 62 
SHADEB 1 933 1 211 3 084 0 006 
SHACUR 1 297 0 874 1 925 0 2 
aOR: adjusted odds ratio; CI: confdence interval. KAM: Knee arthroscopy with 
meniscectomy (medial or lateral); SHADEC: shoulder arthroscopy with decompression; 
KAC: knee arthroscopy 
TABLE: Adjusted odds of reaching the composite outcome* for smokers, by 
procedure  
*Composite outcome: Any cardiac, renal, wound (including all surgical site infections),
sepsis, thromboembolic, or pulmonary complication as recorded in the NSQIP database. 
shoulder and knee arthroscopic sur-
gery for sports injury. 
The National Surgical Quality
Improvement Program (NSQIP)
database was queried retrospectively 
for patients who underwent knee or 
shoulder arthroscopic surgery for
sports injury between 2010-2016.
These patients were identifed using 
the current procedural terminology 
(CPT) codes. This database provides 
an invaluable source of data on a
large sample of patients collected in a 
reliable, systematic way from centers 
across the country.  
D e a t h s  a n d  c o m p l i c a t i o n s  
recorded in the frst 30 days postoper-
atively were included and categorized
as cardiac, renal, wound (including
all surgical site infections), sepsis,
thromboembolic, or pulmonary. A
composite outcome was formed and
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defned as positive if a patient experi-
enced any of the above complications.
Univariate and multivariate analyses 
were performed to determine whether
preoperative smoking was an indepen-
dent risk factor for any of these post-
operative complications individually 
or for the composite outcome. 
The study included 134,822 cases.
In univariate analysis, smoking was
associated with increased rates of com-
plication in knee arthroscopy with
the following: ACL reconstruction
or medial and lateral meniscectomy, 
and shoulder arthroscopy with the
following: debridement, decompres-
sion, or rotator cuf repair. Signifcant
associations then underwent mul-
tivariate analysis, which found that
smoking was an independent risk
factor for any complication/mortality
event in shoulder arthroscopy with
decompression (OR=1.46; 95% CI:
1.030-2.075), shoulder arthroscopy
with debridement (OR=1.933; 95%
CI: 1.211-3.084) and knee arthroscopy
with medial and lateral meniscectomy
(OR=1.97, 95% CI:1.407-2.757).
Preoperative smoking was found
to be an independent risk factor for
complications for several arthroscopic
procedures, though with variability
between types of procedure. In our
study, patients who smoked were
signifcantly younger, and, presum-
ably, healthier. This is a potential
confounder, which may account for
some of the variability in the impact 
smoking had on outcomes between
different procedures. Strengths of
this study include the use of a nation-
ally validated database, with a large
sample size and robust clinical char-
acteristics. Limitations include the
retrospective nature of the study,
lack of data on surgical technique
and simultaneous procedures, 30-day 
follow up window, and reliance of self-
reporting of smoking status. 
Overall, our data highlights that
even in generally low-risk arthroscopic
procedures, preoperative smoking may
increase the risk of potentially serious
perioperative and early-postoperative
complications. Our work adds to the
breadth of literature demonstrating
that smoking is detrimental to patient
outcomes in orthopaedic surgery in
both the short- and long-term. 
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Comparison Between Medical Therapy and 
Endovascular Treatment of the Extracranial Atherosclerotic 
Vertebral Artery Disease: A Systematic Review 
David Daniel,
MSIII
ADVISERS:
Muhammad 
Zeeshan Memon,
MD, and Shahram 
Majidi, MD 
The George Washington University School of
Medicine and Health Sciences 
Atherosclerosis is a common cause
of vertebral artery stenosis leading to 
vertebrobasilar or posterior circula-
tion strokes and transient ischemic
attacks (TIA). About 20 % of ischemic
strokes occur in the vertebrobasilar
circulation.1 Vertebrobasilar circula-
tion perfuses the medulla, cerebellum,
pons, midbrain, thalamus, and occip-
ital cortex. Therefore, atherosclerotic
disease in these vessels can result in 
significant multisystem disability
and death. There are two portions
of the vertebral arter y, extracra-
nial (V1 – V3) and intracranial (V4).
Though the extracranial vertebral
artery disease is generally regarded to
have more benign outcomes as com-
pared to intracranial, 50% of these
patients may have a stroke at initial
presentation while another 26% may 
present with TIAs.2 For decades, the
primary treatment in these patients
has consisted of antiplatelet and
anticoagulation drugs such as aspirin 
and warfarin. However, advances
in endovascular technolog y with
balloon angioplasty or angioplasty
with stent placement have become
efective alternatives. Recent trials
such as the VIST trial have shown
that interventional techniques are
feasible, safe, and efective.3 However,
more evidence is required to reach
a consensus. The aim of the present 
Continued on p. 34 
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study is to compare best medical treat-
ment and the endovascular approach 
in terms of stroke and death rates at 1 
month and at last follow-up. 
We identifed ECVA studies pub-
lished between January 1966 and
December 2017 using a search on
PubMed. The rates of stroke and
stroke and/or death were estimated
for best medical treatment and endo-
vascular treatment at 1 month and
at last follow-up. A random effects
model was used to calculate pooled
proportions (PP) across studies and
95% confdence intervals. A total of 57
reports were included in the analysis, 
eight studies reported outcomes in
patients receiving medical treatment
(362 patients) and forty-nine studies 
reported upon patients treated with
endovascular approach (2142 patients).
The mean age of patients in the
medical group was 65.6 years (range
61.3 - 69.0 years) and 64.1 years (range 
53.5 - 72 years) in the endovascular
group. The 30-day incidence of stroke
was 26 (7.2%) in the medical treat-
ment group compared to 18 (0.84%)
in the endovascular group, resulting 
in a higher risk for patients in the best
medical treatment when compared
to endovascular treatment (p-value
= 0.0001). Similarly, at follow-up, 33
(12.3%) strokes were observed in the 
medical group compared to 51(2.4%) 
in the endovascular group (p-value
= 0.0001). There was also statisti-
cally signifcant diference in stroke
related death in the medical group
Medical Endovascular 
No  of Studies 8 49 
No  of Subjects 362 2142 
Mean Age 65 6 64 1 
Females 84 580 
TABLE 1: Baseline Characteristics 
versus endovascular group 12 (4.5 %) 
vs 1 (0.04%) (p-value =0.001). There
was no statistically signifcant difer-
ence in rates of TIA or death to other 
causes between the two groups. 
Our analysis demonstrated that
endovascular treatment signifcantly 
reduced the risk of stroke and death 
when compared to best medical treat-
ment alone at 30 days and at follow-up.
However, because of the paucity of
long-term outcomes of patients on
standard medical therapy and large
variability observed between endo-
vascular case series, a prospective
randomized trial is warranted in order
**Peri-Op = within 30 days 
TABLE 2: Outcomes 
to better understand the safety and
efcacy of the endovascular treatment
compared to the standard medical
therapy. 
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Medical Endovascular Signifcance 
# of Peri-Op Strokes 26 (7 2%) 18 (0 84%) p = <0 0001 
# of Strokes at Follow-Up 33 (12 3%) 51 (2 4%) p = <0 0001 
# of Stroke Related Deaths at 
Follow-Up 
12 (4 5%) 1 (0 04%) p = 0 001 
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 The Impact of Insulin Dependence on 
Post-Operative Complications in Diabetic Patients 
Undergoing Anatomic Pulmonary Resections  
Harleen 
Marwah, MSII
CO-AUTHORS:
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II, and Ishwarya S 
Mamidi, MS II
ADVISER: Anna 
McLean, MD
The George Washington University School of
Medicine and Health Sciences 
The prevalence of diabetes mellitus
(DM) has been rapidly increasing,
contributing greatly to the burden
of disease in patients and increasing 
economic costs for the healthcare
system in the United States.1,2,3 Impact
on quality of life after surgical treat-
ment is a signifcant concern for many
diabetic patients.4 While the impact 
of DM on various surgical procedures
has been studied, its impact on patient
outcomes following anatomic pulmo-
nary resections remains to be estab-
lished. Therefore, we conducted this 
retrospective analysis to investigate
the impact of insulin dependence on 
DM patients undergoing anatomic
pulmonary resections. 
The National Surgical Quality
Improvement Program surgical reg-
istry maintained by the American
College of Surgeons was queried to
identify patients who under went
pulmonar y resections from 2005
to 2016 by Current Terminolog y
Procedure (CPT) codes. Ultimately, 
18,246 patients were included in the
analyses after excluding patients with
missing data. Patients were stratifed 
into three cohorts by their diabetes
mellitus status — non-diabetics (Non-
DM), non-insulin dependent diabetes
mellitus (NIDDM), and insulin-
dependent diabetes mellitus (IDDM). 
These cohorts were compared for
differences in their demographics,
preoperative comorbidities, and
complication rates using one-way
analysis of variance (ANOVA) for
continuous variables and Pearson’s
Chi-squared tests or Fischer’s exact
tests (expected cell count < 5) for
categorical variables. Multivariate
logistic regression models were gen-
erated with NIDDM and IDDM as
independent risk factors to establish 
risk associations between diabetes
mellitus and specifc adverse events
in these patients. 
Upon analyzing the preoperative 
comorbidities between the three
cohorts, NIDDM and IDDM patients
had significantly higher rates of
dyspnea (p<0.001), chronic obstruc-
tive pulmonary disease (p=0.014),
congestive heart failure (p=0.001),
hypertension requiring medication
management (p<0.001), acute renal
failure (p=0.048), dialysis depen-
dence (p<0.001), open wound/wound
infections (p<0.001), hematologic
disorders (p<0.001), and functional
dependence (p<0.001) compared to
non-diabetic patients. The non-dia-
betic cohort had a signifcantly larger 
proportion of smokers (35.51%) than 
the NIDDM (30.34%) patients and
Continued on p. 37 
DEMOGRAPHICS Non-DM % NIDDM % IDDM % P-value 
15,433 2,017 796 
Sex <0 001 
Female 8447 54 73% 897 44 47% 340 42 71% 
Male 6986 45 27% 1120 55 53% 456 57 29% 
Race <0 001 
American Indian/Alaska Native 101 0 65% 14 0 69% 4 0 50% 
Asian or Pacifc Islander 576 3 73% 104 5 16% 20 2 51% 
Black or African American 1007 6 52% 173 8 58% 95 11 93% 
Hispanic 21 0 14% 1 0 05% 1 0 13% 
White 13728 88 95% 1725 85 52% 676 84 92% 
TABLE 1A:
36 Fusion ♦ 2019
PRE-OPERATIVE COMORBIDITIES 
Smoke 5480 35 51% 612 30 34% 245 30 78% <0 001 
Dyspnea <0 001 
No Dyspnea 11934 77 33% 1487 73 72% 567 71 23% 
At Rest 265 1 72% 35 1 74% 21 2 64% 
Moderate Exertion 3234 20 96% 495 24 54% 208 26 13% 
Ventilator Dependence 29 0 19% 0 0 00% 5 0 63% 0 002 
COPD 3756 24 34% 541 26 82% 216 27 14% 0 014 
Ascites 10 0 06% 1 0 05% 4 0 50% <0 001 
Congestive Heart Failure 75 0 49% 16 0 79% 11 1 38% 0 001 
Hypertension 8291 53 72% 1675 83 04% 672 84 42% <0 001 
Acute Renal Failure 15 0 10% 4 0 20% 3 0 38% 0 048 
Dialysis Dependent 44 0 29% 14 0 69% 16 2 01% <0 001 
Disseminated Cancer 1130 7 32% 111 5 50% 55 6 91% 0 011 
Wound Infection 93 0 60% 23 1 14% 15 1 88% <0 001 
Steroid Use 709 4 59% 82 4 07% 59 7 41% <0 001 
Weight Loss 453 2 94% 57 2 83% 26 3 27% 0 823 
Bleeding Disorder 431 2 79% 83 4 12% 51 6 41% <0 001 
Blood Transfusions 46 0 30% 2 0 10% 5 0 63% 0 057 
Functional Status <0 001 
Independent 15293 99 09% 1981 98 22% 781 98 12% 
Partially Dependent 123 0 80% 33 1 64% 14 1 76% 
Totally Dependent 17 0 11% 3 0 15% 1 0 13% 
OPERATIVE VARIABLES 
ASA Classifcation <0 001 
1-No Disturb 58 0 38% 0 0 00% 1 0 13% 
2-Mild Disturb 3146 20 38% 174 8 63% 32 4 02% 
3-Severe Disturb 10942 70 90% 1575 78 09% 604 75 88% 
4-Life Threat 1284 8 32% 268 13 29% 159 19 97% 
5- Moribund 3 0 02% 0 0 00% 0 0 00% 
Anesthesia Administered 0 065 
Epidural 20 0 13% 3 0 15% 0 0 00% 
General 15385 99 69% 2014 99 85% 793 99 62% 
MAC/IV Sedation 5 0 03% 0 0 00% 2 0 25% 
Other 5 0 03% 0 0 00% 1 0 13% 
Regional 9 0 06% 0 0 00% 0 0 00% 
Spinal 9 0 06% 0 0 00% 0 0 00% 
aValues expressed as Mean ± Standard Deviation  
All other values expressed as (%) and N  
TABLE 1B: 
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IDDM patients (30.78%; p<0.001),
as well as a history of disseminated
cancer (7.32%) compared to either
diabetic cohort (p=0.011; Table 1a-b). 
From the multivariate regression
models, NIDDM patients were found
to be at a significantly higher risk
for reoperation (OR 1.349, 95% CI
1.063-1.712, p=0.014) following pul-
monary resections when compared
to non-diabetics (Table 2). IDDM
patients were at a signifcantly higher 
risk for experiencing pneumonia (OR
1.342, 95% CI 1.033-1.748, p=0.027),
unplanned intubation (OR 1.449,
95% CI 1.063-1.976, p=0.019), venti-
lator dependence for greater than 48 
hours (OR 1.792, 95% CI 1.281-2.507, 
p=0.001), acute renal failure (OR
2.888, 95% CI 1.548-5.389, p=0.001),
strokes (OR 2.353, 95% CI 1.184-4.675,
p=0.015), cardiac arrest (OR 1.94,
95% CI 1.086-3.465, p=0.025), and an 
extended length of hospital day of at 
least 10 days (OR 1.357, 95% CI 1.120-
1.644, p=0.002; Table 2). 
Discussion: Diabetes mellitus
patients had greater risk for numerous
complications than non-diabetics. By
establishing risk associations between
diabetes mellitus and these adverse
outcomes, surgeons are better pre-
pared to handle these potential com-
plications. Targeting glucose levels to 
<200 mg/dL in diabetics may lower the
risk for these serious complications. 
IDDM patients were at an increased 
risk for pneumonia, intubation, ven-
tilator dependence, renal failure,
cardiac arrest, and extended length
of stay, demonstrating the impact of 
insulin dependence on surgical com-
plications. Thus, surgeons can better 
preoperatively plan for these adverse 
events in diabetic patients undergoing
pulmonary resections. 
IDDM NIDDM 
Complication Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value 
Superfcial Incisional SSI 0 699 (0 361-1 354) 0 288 0 835 (0 513-1 360) 0 47 
Deep Incisional SSI 1 338 (0 294-6 093) 0 707 0 868 (0 251-2 996) 0 822 
Organ/Space SSI 0 615 (0 305-1 240) 0 174 0 90 (0 516-1 570) 0 711 
Wound Dehiscence 1 137 (0 140-9 222) 0 905 - -
Pneumonia 1 342 (1 033-1 748) 0 027 0 965 (0 797-1 168) 0 712 
Unplanned Intubation 1 449 (1 063-1 976) 0 019 1 005 (0 791-1 277) 0 966 
Pulmonary Embolism 1 004 (0 461-2 184) 0 993 0 825 (0 516-1 321) 0 424 
Ventilator Dependence 
(48 hours) 
1 792 (1 281-2 507) 0 001 0 824 (0 632-1 075) 0 154 
Progressive Renal 
Insuffciency 
0 485 (0 233-1 01) 0 053 0 741 (0 399-1 376) 0 342 
Acute Renal Failure 2 888 (1 548-5 389) 0 001 1 219 (0 666-2 229) 0 521 
Urinary Tract Infection 0 788 (0 481-1 291) 0 343 0 968 (0 675-1 388) 0 86 
CVA/Stroke 2 353 (1 184-4 675) 0 015 1 141 (0 561-2 319) 0 716 
Cardiac Arrest 1 94 (1 086-3 465) 0 025 1 148 (0 696-1 894) 0 588 
Deep Venous 
Thromboembolism 
1 532 (0 879-2 671) 0 132 0 964 (0 609-1 526) 0 875 
Myocardial Infarction 1 949 (0 961-3 952) 0 064 1 467 (0 867-2 483) 0 153 
Post-Operative Blood 
Transfusions 
0 974 (0 733-1 296) 0 859 0 966 (0 797-1 171) 0 725 
Systemic Sepsis 1 353 (0 729-2 513) 0 338 0 977 (0 684-1 394) 0 897 
Septic Shock 0 697 (0 410-1 184) 0 182 1 111 (0 717-1 721) 0 639 
Return to OR 0 809 (0 602-1 086) 0 158 1 349 (1 063-1 712) 0 014 
Extended Length of Stay
(≥ 10 days) 
1 357 (1 120-1 644) 0 002 1 089 (0 944-1 258) 0 243 
TABLE 2:
REFERENCES: 
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 Intubation Related Vocal Cord Paresis: 
Outcomes from a Patient Cohort 
Ishaan Dharia,
MSII
ADVISER: Steven 
Bielamowicz, MD
The George 
Washington 
University School of
Medicine and Health Sciences 
Vocal cord paresis and paralysis are
recognized complications of endo-
tracheal intubation; the effects of
such complications can range from
quality of life changes such as efortful
speaking, vocal fatigue, and loss of
high register, to more severe outcomes
like aspiration pneumonia and com-
plete voice loss.1 
We conducted a retrospective
study, approved by the institu-
tional review board of The George
Washington University Medical
Faculty Associates. The charts of 62
patients were reviewed for this study.
Each of these subjects was diagnosed
with vocal fold paresis/paralysis based
on fve assessments: patient history,
subjective rating scales, laryngeal
examination, laryngeal electromyog-
raphy (EMG), and acoustic/aerody-
namic measures. 
Subjects were classifed into four
groups based on EMG interpreta-
tions of reinnervation or denervation:
mixed, reinnervation, denervation,
and none. Multiple studies have shown
that signs of reinnervation/denerva-
tion on EMG are indicative of patient
prognosis; however, the duration of
time between the symptom onset and
EMG test date has also been shown to
be correlated with prognosis.2,3 Thus,
the above groupings, plus the duration
of time between the intubation date
Complete Resolution 
No Complete 
Resolution T-test 
Average Glottal Function 
Index (GFI) 
2 89 7 66 p= 6 30E-4 
Average Physical Exam Score 0 1 52 p= 5 16E-09 
TABLE: Differences in Average Post-Treatment GFI and Physical Exam Scores for 
Patients With and Without Complete Resolution of Vocal Cord Weakness 
and EMG date, were combined to
create a new defnition of prognosis
of each subject’s vocal cord paresis/ 
paralysis. Using these criteria, a score
was determined for each patient—a
score closer to 2 indicated a good prog-
nosis while a score closer to 0 indicated
a poor prognosis. Data analysis was
conducted on 3 tiers of patients.
Our analyses of all patients showed
that subjects less than or equal to 60
years of age had an average prognosis
score of 1.21 while subjects above
the age of 60 had a score of 0.79; the
difference between these prognosis
values were statistically significant
at p < 0.05. Our results found that
hypertension was the most common
comorbidity seen in patients who
were diagnosed with a post-intu-
bation vocal cord paresis/paralysis.
Results from the second tier of analysis
showed that of all 38 patients from
whom we had post-treatment data
for, only 9 patients (24%) achieved
complete resolution of their vocal cord
paresis/paralysis (defned as a Glottal
Function Index (GFI) of 7 or below
and a physical exam score of 0). The
average age of subjects that achieved
complete resolution was 54.44 years
and the average age of those that did
not completely recover had an average
age of 59.94. A chi-squared analysis
assessing the relationship between age
at intubation and outcomes showed
no statistically signifcant diferences
(p = 0.05). We also found that patients
with complete resolution of their vocal
cord dysfunction had a post-treatment
average GFI of 2.89, which was 4.77 
points lower than the average GFI
for patients without complete resolu-
tion. This diference was statistically
signifcant at p < 0.05.
This study is one of the first to
use a larger sample of these patients
to analyze trends—using the com-
piled data we were able to show how
various cofactors can be used to
determine both the initial prognosis
and outcomes of these patients. Our
results should help guide physicians
to better prevent, diagnose, and treat
patients with vocal cord injury due to
intubation. 
REFERENCES 
1. Nazal CH, et al. Vocal Cord Paralysis After
Endotracheal Intubation: An Uncommon
Complication of General Anesthesia.
Brazilian J of Anesthesiology (English
Edition) 2018;68(6):637-640. 
2. Parnes SM and Satya-Murti S. Predictive 
Value of Laryngeal Electromyography
in Patients with Vocal Cord Paralysis
of Neurogenic Origin. Lar yngoscope
1985;95(11):1323-1326. 
3. Munin MC, Murry T, and Rosen CA.
Laryngeal Electromyography: Diagnostic
and Prognostic Applications. Otolaryngol
Clin of North Am 2000;33(4):759-770. 
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This study evaluates whether delivery
provider affects maternal and neo-
natal outcomes in nulliparous women
with singleton gestation and a normal
second stage of labor. 
We performed a retrospective
cohort study of term, nulliparous
women with singleton gestations
and cephalic presentation, who had a 
second stage of labor <3 hours in dura-
tion at a single institution. Exclusion 
criteria were intrauterine feta l 
demise, planned cesarean delivery
or suspected major fetal anomaly.
Outcomes were compared by delivery
provider: obstetrician (MD) and certi-
fed nurse midwife (CNM). Primary 
outcome was incidence of cesarean
delivery, with maternal and neonatal 
outcomes compared secondarily.
We evaluated 427 women: 120 with
CNM providers and 307 with MD
providers. Maternal demographics
significantly differed by maternal
age at delivery, race, hypertension,
Delivery Methods 
aOR  11 94 
(95% CI 1 61-87 62 
99 2% 
100% 90 9% 
80% 
60% aOR  0 25 
aOR  NA (95% CI 0 03-1 97 aOR  NA 
20% 
40% 
3 3% 2 9% 2 9% 
0 8% 0 0% 0 0% 0% 
Cesarean NSVD FAVD VAVD 
delivery 
■  MD ■  CNM 
FIGURE: Delivery Methods  aOR- adjusted Odds Ratio, CI-confdence interval, NSVD- 
normal spontaneous vaginal delivery, FAVD- forceps assisted vaginal delivery, VAVD- 
vacuum assisted vaginal delivery 
BMI, epidural use, induction, and
gestational age at delivery. There was 
a significant difference in rates of
normal spontaneous vaginal deliveries
(NSVD): 99.2% in CNM patients and
90.9% in MD patients. Incidence
of cesarean delivery was 0% in the
CNM group and 2.93% in the MD
group. The CNM group had a lower 
incidence of composite maternal
morbidity: 9.17% vs 19.54% in the
MD group. There were no signifcant 
diferences in maternal or neonatal
outcomes.
In term nulliparous women with
singleton gestations who had a normal
second stage, delivery provider did
not signifcantly afect the incidence 
of cesarean delivery but signifcantly 
afected the incidence of normal spon-
taneous vaginal delivery. Most women
delivered vaginally, with 97.07%
of women in the MD group and
100% in the CNM group. Maternal
demographics signifcantly difered
between the two groups, with older
patients and decreased epidural use
in the CNM group. MD patients
had higher rates of hypertension
and induction, as well as higher BMI 
scores. MD and CNM groups had sim-
ilar maternal and neonatal outcomes 
when controlling for confounders. 
Continued on p. 39 
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MD (n=307) CNM (n=120) p-value OR (95% CI) p-value aOR (95% CI) p-value 
Delivery Subtype 
   CD 
   NSVD 
   FAVD
VAVD 
9 (2 93%) 
279 
(90 88%) 
10 (3 26%) 
9 (2 93%) 
0 (0%) 
119 (99 17%) 
1 (0 83%) 
0 (0%) 
0 0668 (*) 
0 0022* 
0 3049 
0 0668 (*) 
NA
11 94 (1 61 – 88 79) 
0 25 (0 03 – 1 97) 
NA 
- 
0 0154*
0 1881 
-
NA
11 94 (1 61 – 87 62) 
0 25 (0 03 – 1 97) 
NA 
- 
0 0154*
0 1881 
-
Chorioamnionitis 20 (6 51%) 3 (2 50%) 0 0986 (*) 0 37 (0 11 – 1 26) 0 1119 0 31 (0 07 – 1 38) 0 1247 
Endometritis 1 (0 33%) 0 (0%) 0 9999  NA - - -
Postpartum 
hemorrhage 
20 (6 51%) 6 (5 00%) 0 5563 0 76 (0 30 – 1 93) 0 5576 0 63 (0 23 – 1 73) 0 3715 
Transfusion 0 (0%) 0 (0%) NA NA - - -
3rd degree lac  12 (3 91%) 2 (1 67%) 0 3669  0 42 (0 09 – 1 89) 0 2565 0 42 (0 09 – 1 92) 0 2641 
4th degree lac  1 (0 33%) 0 (0%) 0 9999  NA - - -
At least 1 negative 
maternal outcome 
60 (19 54%) 11 (9 17%) 0 0096* 0 42 (0 21 – 0 82) 0 0155* 0 38  (0 19 – 0 77) 0 0072* 
NICU admission 10 (3 26%) 7 (5 83%) 0 2697  1 84 (0 68 – 4 95) 0 2274 1 87 (0 69 – 5 03) 0 2167 
CPAP 13 (4 23%) 8 (6 67%) 0 2962 1 62 (0 65 – 4 00) 0 3002 1 64 (0 66 – 4 06) 0 2859 
Sepsis 2 (0 65%) 1 (0 83%) 0 9999  1 28 (0 12 – 14 27) 0 8400 1 30 (0 12 – 14 46) 0 8314 
Seizure 0 (0%) 1 (0 83%) 0 2810  NA - - -
HIE 0 (0%) 2 (1 67%) 0 0785(*)  NA - - -
Shoulder dystocia 6 (1 95%) 1 (0 83%) 0 6787  0 42 (0 05 – 3 54) 0 4262 0 43 (0 05 – 3 59) 0 4336 
Death 0 (0%) 1 (0 83%) 0 2810  NA - - -
At least 1 negative 
neonatal outcome 
21 (6 84%) 10 (8 33%) 0 5930 1 24 (0 57 – 2 71) 0 5936 1 26 (0 57 – 2 76) 0 5683 
MD- medical doctor, CNM- certifed nurse midwife, OR- odds ratio, aOR- adjusted odds ratio, NA: not enough occurrence for accurate 
result; CD- cesarean delivery, NSVD- normal spontaneous vaginal delivery; FAVD- forceps assisted vaginal delivery; VAVD- vacuum 
assisted vaginal delivery; CPAP- continuous positive airway pressure; NICU- neonatal intensive care unit; HIE- hypoxic ischemic 
encephalopathy 
Data are in mean (%) 
TABLE: Perinatal Outcomes 
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Patent Ductus Arteriosus (PDA)
is a congenital heart abnormality,
afecting up to 80% of all Extremely 
Low Birth Weight (ELBW) infants.1 
Surgical repair of this cardiac anomaly
renders the Recurrent Laryngeal
Ner ve v u l nerable to iatrogen ic 
damage, ultimately inducing vocal
cord paralysis.2 Our objectives were
to determine the clinical compliance 
with postoperative screening for vocal
cord paralysis and associated comor-
bidities in premature infants fol-
lowing PDA ligation. Given that vocal
cord paralysis is a known complication
of PDA ligation, an understanding of 
the current screening methodology is
needed for improvement of care. 
A three-year retrospective chart
review was performed for all prema-
ture infants who underwent PDA
ligation at the Children’s National
Health System pediatric hospital.
Vocal cord palsy, otolaryngology
postoperative consultations, and
comorbidities (voice abnormalities,
feeding difculties, gastrostomy tube
placement, and supplemental oxygen
at discharge) were extracted from the 
charts. Standard statistical method-
ology was applied. 
Seventy-four patients were iden-
tified (33M/41F; mean [SD] gesta-
tional age 25.6
[3.5] weeks). Of
vs. 0.09%, p=0.0013) compared to
those who did not. 
It’s important to note, not all
patients who post-operatively pre-
sented with symptoms concerning for
vocal cord paralysis were sufciently 
evaluated. Additionally, the reported 
prevalence of vocal cord paralysis
may be underestimated due to the
these patients, [T]he reported prevalence of vocal cord paralysis
17 infants (23%)
were diagnosed may be underestimated due to the lack of otolaryn-
with vocal cord
p a r a l y s i s ;  1 4  gology evaluation after PDA ligation, highlighting
patients (19%) 
experienced the need for a better screening protocol. 
left-sided vocal
cord paralysis, 2 
patients experienced bilateral vocal
cord paralysis, and 1 patient experi-
enced right-sided vocal cord paralysis.
Despite 33 patients (45%) suffering
from post-operative voice abnor-
malities, defned as a hoarse or weak 
cry, and 48 patients (55%) with docu-
mented feeding difculties, only 27
patients (36%) were evaluated by
otolaryngology for possible vocal cord
paralysis. Patients with known vocal 
cord paralysis had a higher rate of
gastrostomy tube placement (53% vs. 
12%, p= 0.0003), supplemental oxygen
(64% vs. 36%, p= 0.0417), and need for 
chronic ventilation at discharge (18% 
lack of otolaryngology evaluation
after PDA ligation, highlighting the 
need for a better screening protocol. 
Premature infants with known vocal 
cord paralysis after PDA ligation
have greater feeding and respiratory 
comorbidities. Therefore, timely diag-
nosis may improve discharge planning
and patient/parent counseling. 
REFERENCES:
1 Evans N. Diagnosis of patent ductus arte-
riosus in the preterm newborn. Arch Dis 
Child. 1993; 68: 58–61. 
2 Lee K. Essential Otolaryngology: Head and 
Neck Surgery, 8th edn. San Francisco, CA:
McGraw Hill, 2003. 
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Our objective in this study was com-
paring perioperative and functional
outcomes of autologous fascia lata
vs. rectus fascia pubovaginal sling in 
female patients with stress urinary
incontinence (SUI). 
Autologous fascial pubovaginal
slings (AFPVS) are the most widely
used surgical treatment in patients
with complex SUI.1,2 The majority
of series have reported the use of
rectus fascia grafts.3,4 Despite this
convention, the use of fascia lata
has been described as an alterna-
tive with the benefts of minimizing 
postoperative pain and theoretically 
lowering the risk of abdominal com-
plications such as wound infections. 
Furthermore, fascia lata harvest been 
used in patients with signifcant cen-
tral obesity, poor quality abdominal 
fascia or with an extensive history of 
abdominal surgery.5 Despite potential
benefts, fascial lata sling harvest is
associated with its own set of com-
plication related to morbidity from a 
second incision site and concerns with
long term durability.3 To our knowl-
edge, fascia lata slings have never
been assessed in direct comparison
Fascia lata 
pubovaginal sling
N=21 
Rectus fascia 
pubovaginal sling
N=84 
p-value 
Operative time (min) 84 (±29 1) 81 9 (±28 9) 0 68 
Length of stay (hours) 25 (±9 8) 33 7 (±24 3) 0 15 
Estimated blood loss (ml) 91 7 (±90 3) 141 6 (±104 2) 0 04 
Postoperative complications
   Clavien grade 1
   Clavien grade 2
   Clavien grade 3
   Clavien grade 4 or 5 
11 (52 4%)
   11
   1
   0
   0 
41 (48 9%)
   25
   14
   3
   0 
0 81 
Readmission 1 (4 8%) 3 (3 6%) 0 99 
Wound complications
   Seroma
Wound infections 
0 (0%)
   0
   0 
12 (14 3%)
   9*
   4* 
0 12 
*: one patient had both a seroma and a wound infection 
TABLE 1: Perioperative Outcomes 
with rectus fascial slings. The aim of 
the present series is to compare peri-
operative and functional outcomes of 
autologous fascia lata vs. rectus fascia 
pubovaginal sling in female patients 
with SUI. 
Materials and methods: Charts
of all female patients who underwent 
AFPVS for SUI from 2012 to 2017 at 
a single academic center were retro-
spectively reviewed. Patients were
divided into two groups: those with
the autologous sling harvested from
the fascia lata (FL group) and those
with the autologous sling harvested
from the rectus fascia (RF group).
Peri-operative and functional out-
comes were compared.
Results: Between 2012 and 2017,
105 women underwent pubovaginal
slings: 21 using FL and 84 using RF.
Operative time did not differ sig-
nificantly between the FL and RF
groups (84 vs. 81.9 min; p=0.68). There
were more wound complications in
the RF group, but this difference
did not reach statistical signifcance 
(0% vs. 14.3%; p=0.12). The overall
complications rates were comparable
in the FL and RF groups (52.4%
vs. 48.9%; p=0.81), but the propor-
tion of postoperative complications
Clavien grade ≥ 2 tended to be higher 
in the RF group (4.8% vs. 20.2%;
p=0.11). Overall, wound complications
accounted for 29.3% of post-operative
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complications in the RF group (12/41).
The functional outcomes were com-
parable between FL and RF group,
with similar rates of patients cured
of SUI symptoms at 1 month (82.4% 
vs. 76.4%; p=0.74), 1 year (55.6% vs.
63.8%; p=0.76), and the latest follow-
up (66.7% vs. 65.8%; p=0.87). 
When compared to rectus fascia 
harvest for pubovaginal sling, fascia
lata harvest may decrease periop-
erative morbidity, especially wound
complications, without compromising
functional outcomes.
REFERENCES 
1. AUA/SUFU Guideline. Surgical Treat-
ment of Female Stress Urinary Inconti-
nence (SUI): AUA/SUFU Guideline. 2017 
2. Syan R, Brucker BM. Guideline of guide-
lines: urinary incontinence. BJU Int. 2016 
117(1):20-33.
3. Zoorob D, Karram M. Role of autolo-
gous bladder-neck slings: a urog yne-
cology perspective. Urol Clin North Am. 
2012;39(3):311-6. 
4. Bayrak Ö, Osborn D, Reynolds WS,
Dmochowski RR.  Pubovaginal sling
materials and their outcomes. Turk J Urol.
2014;40(4):233-9.
5. Flynn BJ, Yap WT. Pubovaginal sling
using allograft fascia lata versus autograft 
fascia for all types of stress urinary incon-
tinence: 2-year minimum followup. J Urol.
2002;167(2 Pt 1):608-12. 
Fascia lata Rectus fascia 
pubovaginal 
sling
pubovaginal 
sling
p-value 
N=21 N=84 
1-month SUI outcomes 0 74 
   Cured 14 (82 4%) 55 (76 4%)
   Improved 1 (5 9%) 9 (12 5%)
   Unchanged 2 (11 8%) 6 (8 3%)
Worsened 0 2 (2 8%)
   Lost to follow-up 4 12 
1-month de novo self-
catheterization 
3 (17 7%) 21 (28 8%) 0 54 
Change in post-void residual at 1 
month (ml) 
+ 50 9 (±51 5) + 20 5 (±104 8) 0 06 
1-year SUI outcomes 0 76 
   Cured 5 (55 6%) 30 (63 8%)
   Improved 3 (33 3%) 9 (19 2%)
   Unchanged 1 (11 1%) 6 (12 8%)
Worsened 0 2 (4 3%)
   Lost to follow-up 13 37 
1-year de novo self-
catheterization 
1 (11 1%) 3 (6 4%) 0 51 
Change in post-void residual at 1 
year (ml) 
+ 43 6 (±66 5) - 7 (±77 8) 0 18 
Last follow-up SUI outcomes 0 87 
   Cured 12 (66 7%) 48 (65 8%)
   Improved 5 (27 8%) 17 (23 3%)
   Unchanged 1 (14 3%) 6 (8 2%)
Worsened 0 2 (2 7%)
   NA 3 11 
Last follow-up de novo self-
catheterization 
3 (16 7%) 7 (9 6%) 0 41 
Last follow-up change in post-
void residual at 1 year (ml) 
+ 46 (±55 4) +27 4 (±113 5) 0 10 
Mean follow-up (months) 8 5 (±9 5) 14 1 (±15 4) 0 11 
SUI: stress urinary incontinence 
TABLE 2: Functional Outcomes 
44 Fusion ♦ 2019
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    
 
 
 
 
 
 
 
     
 
 
 
 
  
      
  
 
     
     
 
     
 
 
 
 
 
 
 
  
 
 
 
 
Cortical Thickness Asymmetries in MRI-Abnormal Pediatric 
Epilepsy Patients: A Potential Metric for Surgery Outcome  
Natalie Pudalov,
MSII
ADVISERS:
Emanuel
Boutzoukas,1 Maria
Z  Chroneos,1 
Xiaozhen You, PhD,1 
Leigh Sepeta, PhD,1 
William D  Gaillard, MD,1 Madison M  Berl,
PhD1 
1Children’s National Health System 
Neuroanatomical morphometric
analysis in childhood temporal and
extratemporal epilepsy reveals pat-
terns of widespread cortical thin-
ning.1,2 The degree of neocortical
thinning both ipsilateral and contra-
lateral to the focus in epilepsy is asso-
ciated with poor epilepsy surgery out-
come for MRI-normal adult epilepsy 
as well as MRI-abnormal childhood 
epilepsy.3,4 This project extends upon 
previous investigations by looking at 
cortical thickness (CT) differences
in a pre-surgical pediatric epilepsy
population with MRI abnormalities. 
Sagittal T1-weighted MPRAGE
structural MRI scans were performed
on 25 pediatric epilepsy patients (age
7–17 years) with abnormalities on
MRI. All surface-based morpho-
metric processing and analyses were 
conducted using FreeSurfer (FS) 6.0. 
A repeated measures ANOVA was
used to examine the efects of focus 
(temporal or extratemporal), side
(ipsilateral or contralateral), and lobe 
(frontal, temporal, parietal, occipital)
on cortical thickness.  
Repeated measures A NOVA 
revealed a signifcant efect of lobe
(p<.01) such that Temporal CT>
Frontal CT> Occipital CT> Parietal 
CT. There was also a trend towards
significance for the side of focus
(ipsilateral vs. contralateral) and a sig-
nifcant interaction between side and 
lobe (repeated measures ANOVA,
p=.055; p<.05), indicating that CT by 
lobe varied according to whether the 
patient had a temporal or extratem-
poral epilepsy focus. On the ipsilateral
side, the order of greatest CT by lobe 
was: Temporal> Frontal> Parietal>
Occipital. On the contralateral side, 
the occipital lobe was thickest but
the other lobes were consistent in
their order. There were no signifcant 
CT differences related to having a
temporal versus extratemporal focus. 
Across both temporal and extra-
temporal epilepsy groups, we found
that the temporal lobe was thickest
on the ipsilateral side. This may be
because the MRI abnormality which 
w a s  l a r g e l y 
suggesting that thicker ipsilateral CT
is associated with a good surgery out-
come. Here, we observed thinner CT 
on the contralateral side in patients
that largely experienced surgical
success. Future research with larger
sample sizes could investigate the
relationship between CT and dif-
ferent types of MRI abnormality and 
surgery outcomes. 
REFERENCES: 
1. Widjaja, E., Mahmoodabadi, S. Z., Snead, 
O. C., Almehdar, A., & Smith, M. L.
(2011). Widespread Cortical Thinning
in Children with Frontal Lobe Epilepsy.
Epilepsia, 52(9), 1685-1691. 
2. Mueller, S. G., Laxer, K. D., Barakos, J.,
Cheong, I., Garcia, P., & Weiner, M. W. 
(2009). Widespread Neocortical Abnor-
malities in Temporal Lobe Epilepsy with 
and Without Mesial Sclerosis. Neuro-
image, 46(2), 353-359. 
dysplasia con- Seizure onset and duration was associated with thin-
tributed to a
th icker CT. ning of the ipsilateral parietal lobe suggesting that Seizure onset 
and duration perhaps the parietal lobe is vulnerable to long-term w a s  a s s o c i -
a t e d  w i t h effects of ongoing seizure activity. t h i n n i ng of  
the ipsilateral 
parietal lobe
suggesting that perhaps the parietal 
lobe is vulnerable to long-term efects
of ongoing seizure activity. 
Additionally, the majority of this 
sample (84%) were noted to have suc-
cessful surgery outcomes, as quanti-
fed by an Engel Class 1 or 2 designa-
tion post-surgery, a standard metric
indicating seizure freedom or signif-
cant reduction. Thus, our results are 
in accordance with previous research,
3. Bernhardt, B. C., Bernasconi, N., Concha,
L., & Bernasconi, A. (2010). Cortical
Thickness Analysis in Temporal Lobe
Epilepsy. Reproducibility and Relation to 
Outcome. Neurology, 74(22), 1776-1784. 
4. Kamson, D. O., Pilli, V. K., Asano, E.,
Jeong, J. W., Sood, S., Juhász, C., &
Chugani, H. T. (2016). Cortical Thick-
ness Asymmetries and Surgical Outcome 
in Neocortical Epilepsy. Journal of the
Neurological Sciences, 368, 97-103. 
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Although there are reports of the
impact of congestive heart failure
(CHF) on total knee arthroplasty
(TKA) and total hip arthroplasty
(THA), there is a lack of literature
analyzing CHF in hip hemiarthro-
plasty (HHA) procedures. The main
objective of this study was to evaluate
the efect of CHF on risks for compli-
cations following HHA.
T h e  A m e r i c a n  C o l l e g e  o f  
Surgeons National Surgery Quality
I m pr o v em ent  P r o g r a m  ( AC S  -
NSQIP) is a multi-institutiona l
national database tracking 30-day
Operative Variables Control % CHF % P-value 
14095 600 
Days to Operation from 
Admission 
1 607  
± 7 256 
2 998  
± 4 676 
<0 001 
Total Operating Time 
(Minutes) 
79 96  
± 43 440 
79 00  
± 40 680 
0 594 
Total Hospital Stay 
Length (Days) 
7 66  
± 7 912 
11 21  
± 11 560 
<0 001 
Days from Operation to 
Death 
13 57  
± 8 879 
10 74  
± 8 848 
0 004 
Days from Operation to 
Discharge 
6 22  
± 7 026 
8 24  
± 9 621 
<0 001 
Discharge Destination <0 001
   Home 2821 20 01% 103 17 17%
   Other than Home 7803 55 36% 391 65 17%
   Not Reported 3471 24 63% 106 17 67% 
Care Type 0 561 
Inpatient 14024 99 50% 598 99 67% 
Outpatient 71 0 50% 2 0 33% 
patient outcomes and complica-
tions for surgical procedures. The
ACS-NSQIP database was queried
for all patients who had undergone
HHA from 2005 to 2016. Pearson’s
chi-squared tests and Fischer’s exact 
tests were utilized to compare difer-
ences in demographics, comorbidities,
and complication rates. Multivariate 
logistic regression analyses were used
to assess the impact of CHF as an
independent risk factor for postopera-
tive complications following HHA. 
Si x hu nd red H H A pat ients  
(4.08%) had CHF, and this patient
cohort was older (p<0.001) and had a 
larger proportion of males (p<0.001). 
CHF was found to be a significant
TABLE 1: Surgery Related Variables of HHA in Control vs CHF
patients 
independent risk factor for pneu-
monia (OR 1.55, 95% CI 1.146-2.097, 
p=0.004), progressive renal insuffi-
ciency (OR 3.277, 95% CI 1.681-6.387, 
p<0.001), pulmonary embolisms (OR 
2.728, 95% CI 1.256-5.926, p=0.011),
cardiac arrest (OR 3.582, 95% CI
2.128-6.031, p<0.001), extended length
of stay (≥5 days) (OR 1.447, 95% CI
1.218-1.720, p<0.001), readmission (OR
1.294, 95% CI 1.004-1.669, p=0.047),
and mortality (OR 2.189, 95% CI
1.688-2.839, p<0.001). (See Tables 1
and 2.) 
This data illustrates that a known
diagnosis of CHF in patients under-
going hip hemiarthroplasty puts
patients at a signifcantly higher risk
of longer hospital stays following
their procedures. Increased length of
stay (LOS) in orthopedic procedures
is associated with increased post-
operative morbidity (i.e. deep venous
thromboembolisms1) and increases
the cost burden to the health care
system.2 
Continued on p. 46 
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Continued fom p. 45 
Beyond LOS, this study found that
CHF is an independent risk factor
for developing pneumonia following
HHA. A lower threshold of suspicion
for pneumonia development in the
postoperative period should be main-
tained for these patients; more aggres-
sive antibiotic prophylaxis may be
considered for CHF patients in HHA.
Additionally, this study found
CHF to be an independent risk factor
for cardiac arrest. The compensatory
beta-adrenoreceptor stimulation of
the heart to increase stroke volume in
the setting of CHF is associated with
increased risk of arrhythmias and
sudden cardiac death (SCD).3 Heart
failure was also found, unsurprisingly,
in this study to be a signifcant risk
factor for post-surgical mortality in
HHA. In the setting of HHA, we
recommend monitoring patients with
a history of CHF with telemetry/EKG
for evidence of ventricular arrhyth-
mias or other risk factors for SCD
prior to discharge and in follow-up
visits. Cardiac function testing prior to
orthopedic procedures such as HHA
may also be warranted. 
The current study also found an
increased risk of progressive renal
insufficiency due to CHF prior to
HHA. CHF and kidney disease are
tightly associated.4 Furthermore, there
is evidence to suggest that arthroplasty
is associated with decreased kidney
function.5 Therefore, this finding
raises the concern for the need for
careful review of the use of periop-
erative and postoperative medication
usage in HHA patients with history
of CHF. 
Further studies evaluating the
timing of medical optimization of
CHF before undergoing HHA is
warranted. More specific precau-
tionar y measures must be taken
to preemptively address potential
Postoperative Complications Odds Ratio 
95% 
Confdence 
Interval 
P Value 
Superfcial Incisional SSI 1 725 0 625 4 758 0 292 
Deep Incisional SSI 1 014 0 358 2 873 0 979 
Organ/Space SSI 1 091 0 258 4 608 0 905 
Wound Disruption 4 205 0 874 20 234 0 073 
Pneumonia 1 55 1 146 2 097 0 004 
Unplanned Intubation 1 305 0 751 2 267 0 346 
Pulmonary Embolism 2 728 1 256 5 926 0 011 
Ventilator Dependence  
(>48 hours) 
1 032 0 451 2 364 0 94 
Progressive Renal Insuffciency 3 277 1 681 6 387 <0 001 
Acute Renal Failure 1 653 0 705 3 877 0 248 
Urinary Tract Infection 1 064 0 756 1 498 0 722 
CVA/Stroke 1 004 0 397 2 539 0 994 
Cardiac Arrest 3 582 2 128 6 031 <0 001 
Myocardial Infarction 1 622 0 977 2 695 0 062 
Blood Transfusions 1 175 0 964 1 431 0 11 
Deep Venous 
Thromboembolism (DVT) 
1 305 0 591 2 883 0 511 
Systemic Sepsis 1 353 0 798 2 295 0 262 
Septic Shock 1 584 0 817 3 071 0 173 
Death 2 189 1 688 2 839 <0 001 
Return to Operating Room 1 087 0 722 1 637 0 69 
Extended Length of Stay
(≥ 5 days) 
1 447 1 218 1 72 <0 001 
Readmission 1 294 1 004 1 669 0 047 
TABLE 2: Multivariate Analyses Assessing Congestive Heart Failure as an 
Independent Risk Factor for Postoperative Complications 
complications in order to optimize
favorable outcomes. 
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Congenital heart disease is the leading
birth defect, afecting almost 1% of
births each year.1 Moreover, children 
who undergo cardiac surgery with
cardiopulmonary bypass (CPB) show 
signifcant cognitive and behavioral
impairments.2 The subventricular
zone (SVZ) in the postnatal/adult
brain is a ver y crucial region for
neurogenesis and it plays an impor-
tant role in neocortical growth of
the gyrencephalic front lobe during
postnatal life. Our preclinical studies 
have shown that CPB insults can
cause a reduction in the neural stem 
progenitor cell (NSPC) pool.1 Others
have shown that MSCs promote
neurogenesis from SVZ NSPCs in
early and late rodent models.2 The 
aim of this study was to observe the 
impact of mesenchymal stem/stromal
cell (MSC) intra-arterial delivery
through cardiopulmonary bypass
(CPB) on the proliferation of neural 
stem/progenitor cells (NSPC) and
neuroblast migration in the porcine
subventricular zone (SVZ). 
The porcine SVZ resembles its
human counterpart and therefore
FIGURE 1: DCX+ Staining, scale bar: 200 μm 
served as the animal model for this
study. Two-week old piglets (n=12)
were randomly assigned to one of
three groups: (1) Control, (2) Deep
hy potherm ic circu lator y a rrest
(CPB/DHCA), and (3) CPB/DHCA
followed by MSC administration.
MSCs (10x10 6 per kg) were delivered 
intra-arterially through CPB. The
piglet brains were fxed three hours
post-CPB. NSPC proliferation was
determined by SOX2+ and Ki67+
antibodies. Neuroblast and radial-glia
like cells were identifed by DCX+ and
GFAP+ antibodies. The anterior-SVZ
was divided into three tiers which
were then subdivided into ventral
and dorsolateral SVZ. Quantifcation
of the NSPC and neuroblasts in
each tier/region was performed, as
these parameters refect neurogenic 
activity.
CPB/DHCA increased early pro-
liferation of NSPCs. MSC delivery did
not alter CPB-induced increased early
proliferation of NSPCs. However,
MSC delivery reduced the length of 
GFAP+ processes of radial-glia like
cells and the amount of DCX+ neuro-
blasts in tier 1 and increased the den-
sity of DCX+ cells in tiers 2 and 3 where
neuroblasts migrate tangentially
toward the frontal lobe. These fndings
suggest that MSC delivery changes
neuroblast distribution within the
SVZ and promotes neuronal migration
toward the frontal lobe. 
Our data shows that CPB insults 
cause proliferation of SVZ neural
stem/progenitor cells. Moreover, our 
preliminary results suggest that MSC
delivery has the potential to affect
migratory stream of young neurons
in SVZ in the acute phase. To deter-
mine the ameliorative efect of MSC 
delivery on neurogenesis, we will need
to further investigate the SVZ in long
term studies. 
Continued on p. 48 
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Ruptured abdominal aortic aneu-
rysms (AAA) cause around 175,000
deaths globally per year.1 In the U.K., 
AAA rupture comprises 1% of causes 
of death for men over 65 years.2 Several
studies have explored fow-mediated
0 
dilation (FMD) as a biomarker for
endothelial dysfunction, which plays 
a key role in the pathophysiology of
aneurysm development. A previous
study from this group (OxAAA), in
fact, found that decreased FMD of
the right brachial artery was corre-
lated with AAA progression; in addi-
tion, soon after surgical repair of the 
aneurysm, FMD among participants
improved.3 No previous study has
explored whether this improvement
persists long-term, however. The
purpose of this study, therefore, was 
to evaluate the long-term changes in 
endothelial function of a subset of
-5 
TP-3 TP-F1/F2 
FIGURE 1: Pre-surgical FMD values (TP3) vs  Post-surgical long-term follow up FMD 
values (1 year and 2–4 year follow up combined, TP-F1/F2) Analyzed using Wilcoxon 
Sign Rank Test 
participants in the previous study. 
The study was conducted using the
OxAAA database of participants who
had received either an endovascular
(EVAR) or an open AAA repair at The
John Radclife Hospital in Oxford,
U.K. since 2013. Participants who
had received at least a preoperative
and postoperative FMD evaluation
were included in the study (N=43).
Participants were recalled to the
hospital from May-August 2018 for
follow-up collection of blood samples,
and FMD measurement using high-
frequency ultrasound of the brachial 
artery. Arterial diameter was mea-
sured at baseline, during four minutes
of artery occlusion, and immediately 
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after release of occlusion to measure 
FMD. The data were analyzed using 
the software “Brachial Analyzer,”
and results were compared against
participants’ previous FMD values.
The Wilcoxon Sign Rank Test was
used to compare patients’ FMD values
at two time points (pre-surgical and 
1–4-year follow up), while ANOVA
was used to analyze patients’ changes 
in FMD over multiple points of follow
up (pre-surgical, post-surgical, 1-year,
and 2–4-year follow up). 
Demographic information about
this cohort and FMD protocol has
previously been published;3 this sub-
group, however, was 97% male and
100% white, consistent with the UK 
epidemiology of AAAs. The average 
number of days from surgery to follow
up for participants was 996.7. Analysis
showed a statistically significant
increase in FMD among all 43 patients
between 1–4 years after AAA repair 
(p=0.0061) (Figure 1). The following 
figure (Figure 2) demonstrates an
increase in FMD at each point of
follow up after surgery for the 13
participants for which all data points 
were available; however, the small
sample size limits any interpretation 
of statistical signifcance . 
T h i s  s t u d y  d e m o n s t r a t e d  
improved FMD several years after
AAA repair among patients. These
fndings support the hypothesis that 
AAAs are systemic vascular diseases, 
and not simply local, abdominal
pathology. The exact mechanism is
unknown at this time. Current vas-
cular research findings present the
aortic thrombus as a possible source 
of systemic inflammation; another
U.K. cohort study of AAAs that found
that even small, sub-surgical AAAs
substantially increase the risk of MI 
FIGURE 2: Pre-surgical FMD values (TP-3), Post-surgical (TP-5), 1-Year Follow-Up (TP-
F1), and 2–4 Year Follow-Up (TP-F2) FMD % ANOVA Analysis 
-5 
0 
-5 
10 
n=13 
n=43 
Friedman test 
P value 0 0079 
TP-3 TP-F1 
15 
Pre-Surgical, Post-Surgical, 10Year, and 2–4 Year Follow-Up FMD Percent 
TP-F2 TP-5 
FM
D 
%
 
or stroke among patients.4 If AAA is 
indeed a systemic disease, perhaps the
risk of rupture is not the only consid-
eration for timing of surgical interven-
tion. FMD could therefore not only be
used as a cost-efective, reproducible, 
and non-invasive biomarker to aid in 
determinations of surgical interven-
tions, but may serve as a biomarker
for increased cardiovascular disease
risk. Though the power of this study is
limited, it provides the frst evidence 
for long-term improvement in endo-
thelial function after AAA surgery;
further research should build on these
fndings.
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Incidence of metastatic prostate
cancer in the United States has
increased over the past ten years, but 
it is unknown how this trend varies
over time in diferent racial and ethnic
populations.1 Racial and ethnic dis-
parities in prostate cancer incidence 
and mortality are well documented.2,3 
Further examination of diferences
in initial rates of prostate cancer
diagnosis by race/ethnicity is needed 
to distinguish factors precipitating
disparity. 
We identi f ied a l l  men f i rst  
diagnosed w ith prostate ca ncer 
from 2005–15 in the Surveillance,
Epidemiolog y, a nd End Results
(SEER) program of the National
Cancer Institute, which monitors 18 
population-based cancer registries.
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Yearly cancer diagnosis frequency
from 2005 to 2015 was categorized
and analyzed by stage (in situ/local-
ized, regional, and distant), race/ 
ethnicity [White, Asian American/ 
Pacif ic Islander (A API), Black],
and age group (45–54, 55–69, 70-75).
Chi-squared tests and multivariable
logistic regression models were used
for data analysis with p<0.05 consid-
ered signifcant.
In the 10-year study period, the
proportion of regional-stage prostate
0 
2009–12 2013–15 
White Men 
2009–12 2013–15 
Black Men 
Race x Year 
FIGURE 1: Adjusted OR (with 95% confdence interval) for prostate cancer in 2009-
12 and 2013–15 versus 2005–08, stratifed by race Adjusted for age A  Distant vs in 
situ/localized  B  Regional vs in situ/localized  Horizontal black line shows the odds for 
the reference group White, Asian, and Black men’s odds of having an initial diagnosis 
of distant prostate cancer, versus in situ/localized cancer, increased by 106%, 84%, and 
62%, respectively (p= 001), between the early and late years of the study Their odds 
of having an initial diagnosis of regional prostate cancer versus in situ/localized cancer,
increased by 24%, 30%, and 31%, respectively (p= 001) 
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cancer increased from 14.2% to 16.6%
of cases (p<.0001) and distant-stage
increased from 3.3% to 5.8% (p<.0001).
The odds of being diagnosed with
regional-stage prostate cancer in
2013–2015 compared to 2005–08
A 
2 5 
2 
■ 
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■ 
■ 
■ 
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0 5 
2009–12 2013–15 
Black Men 
2009–12 2013–15 
AAPI Men 
Year x Race 
■ 
2 5 
were 1.3 times higher for Black men
(95% CI: 1.2-1.5), 1.3 times higher for 
AAPI men (95% CI: 1.1-1.5), and 1.2
times higher for White men (95%
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e-
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OR
 
1 5 
CI.2-1.3) (Figure 1a). The odds of
being diagnosed with distant-stage
prostate cancer in 2013–15 compared 
to 2005–08 were 1.6 times higher for 
Black men (95% CI: 1.4-1.9), 1.8 times 
higher for AAPI men (95% CI: 1.5-
2.3), and 2.1 times higher for White
men (95% CI: 1.9-2.2) (Figure 1b).
In 2005-2008, 2009-2012, and 2013-
2015 respectively, the odds of being
diagnosed with distant-stage prostate
cancer were 1.8 times higher, 1.7 times
higher, and 1.4 times higher for Black 
men compared to White men (all
respective p<.0001) (Figure 2a), and 1.5
times higher, 1.5 times higher, and 1.4 
times higher for AAPI men compared
to White men (all respective p<.001) 
(Figure 2b). 
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The incidence of late-stage pros-
tate cancer has increased signifcantly
in all U.S. males despite race and
ethnicity. Men from minority groups 
experienced higher rates of newly-
diagnosed distant-stage prostate
cancer within each year group when 
compared to White men, with rates 
declining over time. Regional-stage
prostate cancer increased the most
over time in AAPI and Black men,
while newly diagnosed distant-stage
prostate cancer increased the most
over time in White men. Genetic
variation in disease progression, dif-
ferences in socioeconomic status, and
healthcare access have been posited
as theories for disparities in prostate 
0 5 
0 
2009–12 2013–15 2009–12 2013–15 
Black Men AAPI Men 
Year x Race 
FIGURE 2: Adjusted OR (with 95% confdence interval) for prostate cancer in Black 
and AAPI men when compared to White men, stratifed by year Adjusted for age A 
Distant vs in situ/localized  B  Regional vs in situ/localized  Horizontal black line shows 
the odds for the reference group  In 2005–08, 2009–12, and 2013–15, respectively, the 
odds of having an initial diagnosis of distant prostate cancer, versus in situ/localized,
were 76%, 68%, and 40% higher for Blacks than Whites, and 53%, 52%, and 37% higher 
for AAPI than Whites (p< 001) The odds of initial diagnosis of regional prostate cancer,
versus in situ/localized, were 36%, 28%, and 30% lower for Blacks than Whites (p< 001),
for the respective year groups, while 2009-2012 showed the only signifcantly higher 
odds of regional diagnosis in AAPI compared to whites to be 11% higher (p< 05) 
Continued on p. 52 
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cancer care.2,4,5 Changes in guidelines 
for PSA-based screening may be
responsible for this increase, although
this was not directly investigated.
Based on our fndings and previous
studies, we suggest considering racial 
and ethnic disparities when devel-
oping PSA-based screening guidelines
in an efort to reduce them.2,3 
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FIGURE: n-PRDs from an 
individual with tourniquet-induced 
ischemia The tourniquet was 
removed at 20 min and effects of
reperfusion were noted at 22 min 
A) 5 Hz (at 1 5mA) n-PRDs; nPRD 
AUCs were 0 690, 1 900, and 1 04 
for baseline, 12 min, and 22 min,
respectively  B) n-PRDs from the 2000 
Hz (at 1 5mA) stimulus; nPRD AUC 
values were 0 505, 0 699, and 0 824 
for baseline, 12 min, and 22 min,
respectively  
The rate of chronic pain in the United
States is greater than the combined
rates of diabetes, heart disease, and
cancer, with associated healthcare
costs ranging from $560-$635 billion 
per year.1,2 It is imperative that an
objective assessment tool be devel-
oped to ensure adequate pain eval-
uation and appropriate analgesic
intervention is provided to patients
experiencing chronic pain. 
Pupillary ref lex dilation (PRD)
occurs when an alerting stimulus acti-
vates peripheral nociceptive fbers and
elicits pupillary dilation. Preliminary
data indicates that a unique PRD
(nPRD) can be produced by depolar-
izing sensory nerves (Aβ, Aδ, and C
fbers) via non-noxious neurospecifc 
electrical stimuli at particular fre-
quencies. The amplitude of the nPRD
correlates with pain self-report and
the area under the curve (AUC) of the
nPRD refects nerve fber sensitivity. 
These fndings suggest that the AUC 
could function as a metric of nerve
fber sensitivity and that the nPRD
has potential utility in objective
assessment of pain characteristics,
including type and intensity. 
In this pilot study of healthy
adult subjects, infrared pupillometry 
was used to evaluate whether the
nPRD was refective of known dif-
ferences in nerve fiber physiology
under tourniquet-induced ischemic
conditions. Changes in sensory nerve 
fber activity occur in ischemic envi-
ronments due to factors such as degree
of myelination.3 At a baseline state,
activated, myelinated Aβ touch fbers
inhibit transmission of presynaptic
pain signals by unmyelinated, noci-
ceptive C-fibers to diminish pain
sensation.5 However, in an ischemic
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environment, Aβ fbers are not acti-
vated. Thus, there is no suppression
of C-fibers, resulting in stable or
increased pain. It was hypothesized
that this phenomenon could be quan-
tifed by the nPRD AUC for each fber
type and that tourniquet application 
would cause decreased Aβ sensitivity
and increased C-fber sensitivity (see 
Table). 
A baseline electrical stimulus for 
each subject was determined by their 
perception threshold. For baseline
nPRD measurement, each fber type 
was assessed using perception inten-
sity at a specifc activating stimulation
frequency (C fber at 5 Hz, Aδ at 250 
Hz, and Aβ at 2000 Hz). A tourniquet
was then placed on the subject’s upper
arm to induce ischemia, and the same 
nPRD measurements were repeated 
at 5-minute intervals for each fiber
type. The tourniquet was removed at 
20 minutes, and fnal measurements 
were taken during reperfusion. 
In this pilot study, five subjects
demonstrated the hy pothesized 
outcome. As demonstrated in the
Figure, at 12 minutes after tourniquet 
placement the Aβ nPRD AUC was
diminished while the C-fber nPRD 
AUC was significantly increased
from baseline. This suggests that
Time point ΔAUC of C-fber (5Hz) ΔAUC of Aβ fber (2000Hz) 
Baseline - -
Before Tourniquet Removal  
After Tourniquet Removal  
TABLE: Expected Change in nPRD AUC for Each Nerve Fiber Type at Different Time 
Point 
ischemia resulted in removal of Aβ
regulation and disinhibition of the
C-fiber. During the reperfusion
period, the C-f iber nPRD AUC
decreased towards baseline indicating
a return of Aβ suppression. During 
this reperfusion period, the Aβ nPRD
AUC increased to refect heightened 
sensitivity. For all fve subjects, there 
was a signifcant diference between 
the Aβ nPRD AUC values (p=0.024) 
and a diference trending towards sig-
nifcance between the C-fber nPRD 
AUC values (p=0.091) at the three
time points. 
These results indicate that the
nPRD has potential to detect modu-
lation of nerve fber sensitivity. The
data from subsequent trials will help 
determine whether infrared pupil-
lometry in conjunction with selec-
tive neurostimulation can be used to 
objectively measure and monitor pain. 
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 Laparoscopic Hand-Assisted Resection of a 
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Schwannomas are benign tumors of
the peripheral nerve sheath. They fre-
quently occur in the head, neck, and 
extremities.1 Schwannomas within
adrenal glands are extremely rare, with
only 42 reports. The majority of cases 
have been discovered incidentally
and do not demonstrate increased
incidence in any age group or gender.2 
Importantly, despite their association
with the adrenal medulla all previous 
cases except for one report no clinical
or biochemical evidence of hormonal 
activity.3 Diferentiation of schwan-
nomas from other nonfunctional
adrenal masses (adrenal adenoma,
adrenocortical carcinoma, adrenal
metastasis, adrenal myolipoma, and
neuroblastomas) is challenging and
imaging alone is insufcient.4 Current
guidelines state that the management
of adrenal incidentalomas should
consider the tumor size and associated
symptoms, where masses larger than 6
cm or those causing symptoms should
be resected while masses smaller than
4 cm should be closely followed with 
imaging.5 
A previously healthy 37-year-
old male with no significant past
medical history initially presented to 
his primary care physician with new 
onset mild abdominal discomfort
for which he used omeprazole with
only modest relief. An abdominal
ultrasound was obtained and dem-
onstrated a mass in the right-upper
quadrant. A subsequent abdominal/ 
pelvis CT study demonstrated a
heterogenous 4.3 cm mass adjacent
to the right kidney and abutting the 
inferior vena cava and porta hepatis 
with no evidence of invasion into any 
structures. An ultrasound-guided
transabdominal biopsy was obtained 
and demonstrated
a spindle cell neo-
Kocher maneuver was performed
to refect and retract the duodenum 
and gain access into the retroperito-
neal space. The mass was dissected
free and removed, which required
dividing a portion of the right adrenal
gland. Hemostasis was achieved, inci-
sions were repaired, and the patient
recovered well and was discharged
home two days later without any
complications. 
Gross examination of the resected
specimen demonstrated an encapsu-
lated 48 g mass with a heterogenous 
plasm that was con- While biochemically and hormonally inert,
sistent with schwan-
noma. During his these adrenal tumors cannot be defnitively
pre-surgical evalu-
ation, the patient diagnosed or differentiated from other adrenal
denied headaches,
palpitations, or his- masses without surgical resection and histo-
tory of hypertension. 
He had no surgical pathologic studies.
history; he was only 
taking intermittent
omeprazole; he was a former smoker; 
and his family history was remarkable
for leukemia, diabetes mellitus, and
hypertension. His physical exam was 
benign, with only a mildly elevated
systolic blood pressure and no signif-
cant fndings on the abdominal exam.
Pre-surgical labs were within normal 
limits. Therefore, surgical resection
was discussed for defnitive diagnosis 
and treatment. 
The patient was consented for
a laparoscopic hand-assisted resec-
tion of the retroperitoneal mass.
Upon entering the abdominal cavity, 
the mass was easily identified as it
protruded anteriorly adjacent to
the hepatoduodenal ligament. A
tan-white-orange and partially-cystic
interior. Histopathologic examina-
tion demonstrated a spindle cell
neoplasm with neural diferentiation 
and areas of high density (Antoni A) 
and low density (Antoni B) cellularity 
surrounded by adrenal medulla tissue.
Im munoh istochem ica l sta in ing  
demonstrated a mass that was dif-
fusely positive for S-100 and SOX10; 
and negative for CD117/c-kit and
HMB-45. Together, these data sup-
port the diagnosis of intra-adrenal
schwannoma. 
Adrenal schwannomas are a rare
entity that have only been reported 42
times in the medical literature. While
biochemically and hormonally inert, 
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these adrenal tumors cannot be defn-
itively diagnosed or differentiated
from other adrenal masses without
surgical resection and histopathologic
studies. Therefore, adrenal inciden-
talomas pose a clinical challenge as
their discovery requires maintaining 
a broad diferential diagnosis which
includes benign schwannomas and
malignant adrenal neoplasms. 
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Microsurgical reconstruction via
free tissue transfer (FTT) is the last 
option for closure of nonhealing,
lower extremity ( LE) wounds.1–3 
Unfortunately, amputation may be
required even if FTT is successful.
Thus, assessing amputation risk
before reconstruction would help sur-
geons profle patient risk and direct
salvage eforts with outcome-expec-
tations. However, there is a paucity
of literature regarding microsurgical 
outcomes in chronic wound patients. 
The purpose of this study was to eval-
uate risk factors for major amputation
following LE FTT for closure in a
chronic wound population.
Between April 2011 and January
2018, 135 LE FTT procedures were
performed by the corresponding
author for soft tissue coverage of
nonhealing wounds. We studied the 
relationship of patient demographics,
wound characteristics, and periop-
erative traits with limb-salvage and
ambulation rates.
Overall microsurgical success was 
96.3% (130/135) and limb salvage rate 
was 86.7% (117/135). Comorbidities sig-
nifcant for amputation were diabetes
(p=0.009), COPD (p=0.002), ESRD
(p=0.007), and PVD (0.02). Only hind-
foot wound-location was signifcant 
for amputation (p=0.006). Signifcant
perioperative traits included elevated 
platelet count on day of closure (332.8 
vs 257.8, p=0.01) gracilis f lap-type
(p=0.03). Infectious complication was
the only postoperative complication 
predictive of amputation (p=0.007). 
By h ig h l ig hti ng patient a nd 
perioperative traits that increase
risk of amputation, these data help
clinicians foreshadow the trajectory
of wound closure and limb salvage.
Furthermore, these results are a
first-step to creating protocolized
risk-stratifcation recommendations
for patients undergoing LE FTT for 
complex, nonhealing wounds. To
this end, future work will include risk 
analysis for individual risk factors. 
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 medical education: 
Sustainable Development Goals and Mental Health 
Knowledge Among First Year Medical Students 
Most people with mental health 
problems want to have paid 
employment 
If a friend has a mental health problem,
I know what advice to give them to 
professional help 
Medication can be an effective treatment 
for people with mental health problems 
Psychotherapy can be an effective 
treatment for people with mental health 
problems 
People with severe mental health 
problems can fully recover 
Most people with mental health 
problems go to a health care 
professional to get help 
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FIGURE 1: MAKS Results of First-Year MD Student Baseline Knowledge of Mental Health Biopsychosocial Factors 
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The United Nations Sustainable
Development Goals for 2030 high-
lights the impact of mental health
illnesses by including goals for the
prevention and treatment of behav-
ioral, developmental, and neurological
disorders.1 One way to measure the
progress of these goals is to monitor 
a foundational indicator such as
mental health literacy among medical
students. This study aims to look
specifically at f irst year medical
students (MS1s) to determine their
mental health knowledge, as well as
their attitudes towards mental health 
biopsychosocial factors. 
Fifty-nine frst-year medical stu-
dents at the George Washington
University School of Medicine and
Helath Sciences were selected to par-
ticipant in this study prior to the onset
of the behavioral sciences section of 
the curriculum, allowing the assess-
ment of baseline knowledge. The frst-
years underwent a baseline assess-
ment, an intervention to introduce
negative mental health outcomes, as 
well as a post intervention assessment.
The baseline assessments included the
Mental Health Knowledge Schedule 
(MAKS) and the Attitudes Towards 
Seeking Professional Psychological
Help Scale (ATSPPH). MAKS is
designed to assess confdence of one’s 
knowledge of the biopsychosocial
factors of mental illness, as well as
the ability to identify terms that are 
defned as mental illnesses under the 
Diagnostic and Statistical Manual of 
Mental Disorders, 5th Edition (DSM-
5).2 ATSPPH assesses perceptions
towards mental health biopsychoso-
cial factors, also making it ideal as a 
post intervention assessment.3 The 
program intervention itself aimed to 
introduce students to negative mental
health outcomes such as demoraliza-
tion, burnout, depression, and depen-
dency; as well as the diferent strate-
gies that can be applied to address
the diferent negative mental health 
outcomes.
While this investigation looks at 
many factors, there are three main
fndings that merit the greatest atten-
tion. The frst is that there is great
discordance to the statement “Most 
people with mental health problems 
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FIGURE 2: MAKS Results of First-Year MD Student Baseline Identifcation of Mental Health Disorders 
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